0001551152falseDecember 312024Q3http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTaxhttp://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTaxhttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTaxhttp://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTaxhttp://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTaxhttp://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTaxhttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNethttp://fasb.org/us-gaap/2024#MoneyMarketFundsMemberhttp://fasb.org/us-gaap/2024#MoneyMarketFundsMemberhttp://fasb.org/us-gaap/2024#Revenueshttp://fasb.org/us-gaap/2024#Revenueshttp://fasb.org/us-gaap/2024#Revenueshttp://fasb.org/us-gaap/2024#Revenueshttp://fasb.org/us-gaap/2024#Revenueshttp://fasb.org/us-gaap/2024#Revenueshttp://fasb.org/us-gaap/2024#Revenueshttp://fasb.org/us-gaap/2024#Revenues1xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiso4217:EURiso4217:SEKiso4217:CADiso4217:CHFabbv:wholesalerabbv:lawsuitabbv:companyabbv:claimabbv:claimsabbv:segment00015511522024-01-012024-09-300001551152exch:XCHIus-gaap:CommonStockMember2024-01-012024-09-300001551152exch:XNYSus-gaap:CommonStockMember2024-01-012024-09-300001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2024-01-012024-09-300001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2024-01-012024-09-300001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2024-01-012024-09-300001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2024-01-012024-09-300001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2024-01-012024-09-3000015511522024-10-2800015511522024-07-012024-09-3000015511522023-07-012023-09-3000015511522023-01-012023-09-3000015511522024-09-3000015511522023-12-310001551152us-gaap:CommonStockMember2023-06-300001551152us-gaap:TreasuryStockCommonMember2023-06-300001551152us-gaap:AdditionalPaidInCapitalMember2023-06-300001551152us-gaap:RetainedEarningsMember2023-06-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001551152us-gaap:NoncontrollingInterestMember2023-06-3000015511522023-06-300001551152us-gaap:CommonStockMember2023-07-012023-09-300001551152us-gaap:TreasuryStockCommonMember2023-07-012023-09-300001551152us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001551152us-gaap:RetainedEarningsMember2023-07-012023-09-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001551152us-gaap:NoncontrollingInterestMember2023-07-012023-09-300001551152us-gaap:CommonStockMember2023-09-300001551152us-gaap:TreasuryStockCommonMember2023-09-300001551152us-gaap:AdditionalPaidInCapitalMember2023-09-300001551152us-gaap:RetainedEarningsMember2023-09-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001551152us-gaap:NoncontrollingInterestMember2023-09-3000015511522023-09-300001551152us-gaap:CommonStockMember2024-06-300001551152us-gaap:TreasuryStockCommonMember2024-06-300001551152us-gaap:AdditionalPaidInCapitalMember2024-06-300001551152us-gaap:RetainedEarningsMember2024-06-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001551152us-gaap:NoncontrollingInterestMember2024-06-3000015511522024-06-300001551152us-gaap:CommonStockMember2024-07-012024-09-300001551152us-gaap:TreasuryStockCommonMember2024-07-012024-09-300001551152us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001551152us-gaap:RetainedEarningsMember2024-07-012024-09-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001551152us-gaap:NoncontrollingInterestMember2024-07-012024-09-300001551152us-gaap:CommonStockMember2024-09-300001551152us-gaap:TreasuryStockCommonMember2024-09-300001551152us-gaap:AdditionalPaidInCapitalMember2024-09-300001551152us-gaap:RetainedEarningsMember2024-09-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001551152us-gaap:NoncontrollingInterestMember2024-09-300001551152us-gaap:CommonStockMember2022-12-310001551152us-gaap:TreasuryStockCommonMember2022-12-310001551152us-gaap:AdditionalPaidInCapitalMember2022-12-310001551152us-gaap:RetainedEarningsMember2022-12-310001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001551152us-gaap:NoncontrollingInterestMember2022-12-3100015511522022-12-310001551152us-gaap:CommonStockMember2023-01-012023-09-300001551152us-gaap:TreasuryStockCommonMember2023-01-012023-09-300001551152us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001551152us-gaap:RetainedEarningsMember2023-01-012023-09-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001551152us-gaap:NoncontrollingInterestMember2023-01-012023-09-300001551152us-gaap:CommonStockMember2023-12-310001551152us-gaap:TreasuryStockCommonMember2023-12-310001551152us-gaap:AdditionalPaidInCapitalMember2023-12-310001551152us-gaap:RetainedEarningsMember2023-12-310001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001551152us-gaap:NoncontrollingInterestMember2023-12-310001551152us-gaap:CommonStockMember2024-01-012024-09-300001551152us-gaap:TreasuryStockCommonMember2024-01-012024-09-300001551152us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001551152us-gaap:RetainedEarningsMember2024-01-012024-09-300001551152us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001551152us-gaap:NoncontrollingInterestMember2024-01-012024-09-300001551152us-gaap:SubsequentEventMember2024-10-282024-10-280001551152abbv:CerevelTherapeuticsMember2024-08-010001551152abbv:CerevelTherapeuticsMember2024-08-012024-08-0100015511522024-08-012024-08-010001551152abbv:PfizerLicenseAgreementMemberMember2024-08-012024-09-300001551152abbv:CerevelTherapeuticsMember2024-08-012024-09-300001551152us-gaap:RestrictedStockUnitsRSUMember2024-08-012024-09-300001551152abbv:CerevelTherapeuticsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-08-012024-09-300001551152abbv:ImmunoGenMember2024-02-120001551152abbv:ImmunoGenMember2024-02-122024-02-1200015511522024-02-122024-02-120001551152abbv:ImmunoGenMember2024-02-122024-03-310001551152abbv:ImmunoGenMember2024-02-122024-09-300001551152us-gaap:RestrictedStockUnitsRSUMember2024-02-122024-09-300001551152abbv:ImmunoGenMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-02-122024-09-300001551152abbv:ImmunoGenMember2024-07-012024-09-300001551152abbv:ImmunoGenMember2023-07-012023-09-300001551152abbv:ImmunoGenMember2024-01-012024-09-300001551152abbv:ImmunoGenMember2023-01-012023-09-300001551152abbv:OtherCollaborationArrangementsMemberus-gaap:CollaborativeArrangementMember2024-07-012024-09-300001551152abbv:OtherCollaborationArrangementsMemberus-gaap:CollaborativeArrangementMember2023-07-012023-09-300001551152abbv:OtherCollaborationArrangementsMemberus-gaap:CollaborativeArrangementMember2024-01-012024-09-300001551152abbv:OtherCollaborationArrangementsMemberus-gaap:CollaborativeArrangementMember2023-01-012023-09-300001551152us-gaap:CollaborativeArrangementMember2024-07-012024-09-300001551152us-gaap:CollaborativeArrangementMember2023-07-012023-09-300001551152us-gaap:CollaborativeArrangementMember2024-01-012024-09-300001551152us-gaap:CollaborativeArrangementMember2023-01-012023-09-300001551152abbv:CelsiusTherapeuticsMember2024-06-012024-06-300001551152abbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2024-09-300001551152abbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2024-01-012024-09-300001551152abbv:JanssenBiotechIncMember2024-01-012024-09-300001551152country:USabbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2024-07-012024-09-300001551152country:USabbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2023-07-012023-09-300001551152country:USabbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2024-01-012024-09-300001551152country:USabbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2023-01-012023-09-300001551152abbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2024-07-012024-09-300001551152abbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2023-07-012023-09-300001551152abbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2023-01-012023-09-300001551152abbv:JanssenBiotechIncMemberus-gaap:CollaborativeArrangementMember2023-12-310001551152abbv:GenentechInc.Member2024-01-012024-09-300001551152abbv:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2024-07-012024-09-300001551152abbv:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2023-07-012023-09-300001551152abbv:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2024-01-012024-09-300001551152abbv:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2023-01-012023-09-300001551152country:USabbv:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2024-07-012024-09-300001551152country:USabbv:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2023-07-012023-09-300001551152country:USabbv:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2024-01-012024-09-300001551152country:USabbv:GenentechInc.Memberus-gaap:CollaborativeArrangementMember2023-01-012023-09-300001551152us-gaap:DevelopedTechnologyRightsMember2024-09-300001551152us-gaap:DevelopedTechnologyRightsMember2023-12-310001551152us-gaap:LicensingAgreementsMember2024-09-300001551152us-gaap:LicensingAgreementsMember2023-12-3100015511522023-08-290001551152us-gaap:DevelopedTechnologyRightsMemberabbv:ImbruvicaMember2023-08-290001551152abbv:ImbruvicaMember2023-07-012023-09-300001551152abbv:AGN151607Member2023-01-012023-03-3100015511522023-01-012023-03-310001551152abbv:OtherRestructuringPlansMember2024-07-012024-09-300001551152abbv:OtherRestructuringPlansMember2024-01-012024-09-300001551152abbv:OtherRestructuringPlansMember2023-07-012023-09-300001551152abbv:OtherRestructuringPlansMember2023-01-012023-09-300001551152abbv:OtherRestructuringPlansMember2023-12-310001551152abbv:OtherRestructuringPlansMember2024-09-300001551152abbv:AllerganIntegrationPlanMember2023-12-310001551152abbv:AllerganIntegrationPlanMember2023-01-012023-09-300001551152us-gaap:CostOfSalesMemberabbv:AllerganIntegrationPlanMember2023-07-012023-09-300001551152us-gaap:CostOfSalesMemberabbv:AllerganIntegrationPlanMember2023-01-012023-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMemberabbv:AllerganIntegrationPlanMember2023-07-012023-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMemberabbv:AllerganIntegrationPlanMember2023-01-012023-09-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMemberabbv:AllerganIntegrationPlanMember2023-07-012023-09-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMemberabbv:AllerganIntegrationPlanMember2023-01-012023-09-300001551152us-gaap:EmployeeSeveranceMemberabbv:AllerganIntegrationPlanMember2023-07-012023-09-300001551152us-gaap:EmployeeSeveranceMemberabbv:AllerganIntegrationPlanMember2023-01-012023-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-09-300001551152us-gaap:TreasuryLockMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310001551152abbv:CrossCurrencySwapContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-12-310001551152us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2024-09-300001551152us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2023-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001551152us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001551152us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMember2024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMember2023-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-12-310001551152us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2024-09-300001551152us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310001551152us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMember2024-09-300001551152us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMember2023-12-310001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001551152abbv:CrossCurrencySwapContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300001551152abbv:CrossCurrencySwapContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300001551152abbv:CrossCurrencySwapContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-09-300001551152abbv:CrossCurrencySwapContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001551152us-gaap:CostOfSalesMember2024-09-300001551152us-gaap:InterestExpenseMember2024-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2024-07-012024-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2024-01-012024-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2023-07-012023-09-300001551152us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2023-01-012023-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-07-012024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-01-012023-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-07-012023-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-01-012024-09-300001551152us-gaap:TreasuryLockMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-09-300001551152us-gaap:TreasuryLockMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300001551152us-gaap:TreasuryLockMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300001551152us-gaap:TreasuryLockMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001551152abbv:CrossCurrencySwapContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300001551152abbv:CrossCurrencySwapContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300001551152abbv:CrossCurrencySwapContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-09-300001551152abbv:CrossCurrencySwapContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001551152us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001551152us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-09-300001551152us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300001551152us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300001551152us-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMember2024-07-012024-09-300001551152us-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMember2023-07-012023-09-300001551152us-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMember2024-01-012024-09-300001551152us-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMember2023-01-012023-09-300001551152us-gaap:FairValueMeasurementsRecurringMember2024-09-300001551152us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001551152us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001551152us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001551152us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2024-09-300001551152us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001551152us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001551152us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001551152us-gaap:FairValueMeasurementsRecurringMember2023-12-310001551152us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001551152us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001551152us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001551152us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2023-12-310001551152us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001551152us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001551152us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001551152us-gaap:MeasurementInputDiscountRateMembersrt:MinimumMember2024-09-300001551152us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMember2024-09-300001551152us-gaap:MeasurementInputDiscountRateMembersrt:WeightedAverageMember2024-09-300001551152us-gaap:MeasurementInputDiscountRateMembersrt:MinimumMember2023-12-310001551152us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMember2023-12-310001551152us-gaap:MeasurementInputDiscountRateMembersrt:WeightedAverageMember2023-12-310001551152abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMembersrt:MinimumMember2024-09-300001551152abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMembersrt:MaximumMember2024-09-300001551152abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMembersrt:WeightedAverageMember2024-09-300001551152abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMembersrt:MinimumMember2023-12-310001551152abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMembersrt:MaximumMember2023-12-310001551152abbv:ProbabilityofPaymentforRoyaltiesbyIndicationMembersrt:WeightedAverageMember2023-12-310001551152abbv:ProjectedYearofPaymentsMembersrt:MinimumMember2024-09-300001551152abbv:ProjectedYearofPaymentsMembersrt:MaximumMember2024-09-300001551152abbv:ProjectedYearofPaymentsMembersrt:WeightedAverageMember2024-09-300001551152abbv:ProjectedYearofPaymentsMembersrt:MinimumMember2023-12-310001551152abbv:ProjectedYearofPaymentsMembersrt:MaximumMember2023-12-310001551152abbv:ProjectedYearofPaymentsMembersrt:WeightedAverageMember2023-12-310001551152abbv:ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMembersrt:MaximumMember2023-12-310001551152us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-09-300001551152us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300001551152us-gaap:FairValueInputsLevel1Member2024-09-300001551152us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300001551152us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300001551152us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310001551152us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001551152us-gaap:FairValueInputsLevel1Member2023-12-310001551152us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001551152us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001551152us-gaap:AccountsReceivableMember2024-01-012024-09-300001551152abbv:PrincipalUSCustomersMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-09-300001551152abbv:PrincipalUSCustomersMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001551152abbv:SeniorNotesIssuedIn2024Memberus-gaap:SeniorNotesMember2024-09-300001551152abbv:SeniorNotesIssuedIn2024Member2024-09-300001551152abbv:SeniorNotesDue2027Memberus-gaap:SeniorNotesMember2024-02-120001551152abbv:A4.80SeniorNotesDue2029Memberus-gaap:SeniorNotesMember2024-02-120001551152abbv:A4.95SeniorNotesDue2031Memberus-gaap:SeniorNotesMember2024-02-120001551152abbv:A5.05SeniorNotesDue2034Memberus-gaap:SeniorNotesMember2024-02-120001551152abbv:A5.35SeniorNotesDue2044Memberus-gaap:SeniorNotesMember2024-02-120001551152abbv:A5.40SeniorNotesDue2054Memberus-gaap:SeniorNotesMember2024-02-120001551152abbv:A5.50SeniorNotesDue2064Memberus-gaap:SeniorNotesMember2024-02-120001551152abbv:SeniorNotesIssuedIn2024Memberus-gaap:SeniorNotesMember2024-02-120001551152abbv:December2023BridgeCreditFacilityMember2023-12-060001551152abbv:A364DayTermLoanCreditAgreementMember2023-12-210001551152abbv:December2023TermLoanCreditAgreementMember2024-01-012024-03-310001551152us-gaap:LoansPayableMember2024-01-012024-03-310001551152abbv:A2.5ConvertibleSeniorNoteMemberus-gaap:SeniorNotesMember2024-09-300001551152abbv:FDAApprovalMember2024-09-300001551152abbv:SeniorEuroNotesDue2024At1.375Memberus-gaap:LoansPayableMember2024-05-012024-05-310001551152abbv:SeniorEuroNotesDue2024At1.375Memberus-gaap:SeniorNotesMember2024-05-310001551152abbv:SeniorEuroNotesDue2024At1.250PercentMemberus-gaap:LoansPayableMember2024-06-012024-06-300001551152abbv:SeniorEuroNotesDue2024At1.250PercentMemberus-gaap:SeniorNotesMember2024-06-300001551152abbv:SeniorEuroNotesDue2024At3.85PercentMemberus-gaap:LoansPayableMember2024-06-012024-06-300001551152abbv:SeniorEuroNotesDue2024At3.85PercentMemberus-gaap:SeniorNotesMember2024-06-300001551152us-gaap:LoansPayableMember2024-09-300001551152us-gaap:SubsequentEventMember2024-10-012024-12-310001551152abbv:FloatingRateTermLoanTrancheDueMay2023RefinancedMemberus-gaap:LoansPayableMember2023-01-012023-01-310001551152abbv:SeniorNotesDue2023At2.800PercentMemberus-gaap:SeniorNotesMember2023-03-012023-03-310001551152abbv:SeniorNotesDue2023At2.800PercentMemberus-gaap:SeniorNotesMember2023-01-310001551152abbv:SeniorNotesDue2023At2.850PercentMemberus-gaap:LoansPayableMember2023-05-012023-05-310001551152abbv:SeniorNotesDue2023At2.850PercentMemberus-gaap:SeniorNotesMember2023-05-310001551152us-gaap:CommercialPaperMember2024-07-012024-09-300001551152us-gaap:CommercialPaperMember2023-12-310001551152us-gaap:CommercialPaperMember2024-09-300001551152us-gaap:CommercialPaperMember2024-01-012024-09-300001551152us-gaap:RevolvingCreditFacilityMember2023-01-012023-02-280001551152us-gaap:RevolvingCreditFacilityMember2023-03-012023-03-310001551152us-gaap:RevolvingCreditFacilityMember2023-02-280001551152us-gaap:RevolvingCreditFacilityMember2024-09-300001551152us-gaap:RevolvingCreditFacilityMember2023-12-310001551152us-gaap:PensionPlansDefinedBenefitMember2024-07-012024-09-300001551152us-gaap:PensionPlansDefinedBenefitMember2023-07-012023-09-300001551152us-gaap:PensionPlansDefinedBenefitMember2024-01-012024-09-300001551152us-gaap:PensionPlansDefinedBenefitMember2023-01-012023-09-300001551152us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-07-012024-09-300001551152us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-07-012023-09-300001551152us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-09-300001551152us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-09-300001551152us-gaap:CostOfSalesMember2024-07-012024-09-300001551152us-gaap:CostOfSalesMember2023-07-012023-09-300001551152us-gaap:CostOfSalesMember2024-01-012024-09-300001551152us-gaap:CostOfSalesMember2023-01-012023-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001551152us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300001551152us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001551152us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001551152us-gaap:EmployeeStockOptionMember2024-09-300001551152abbv:RestrictedStockUnitsAndPerformanceSharesMember2024-01-012024-09-300001551152abbv:RestrictedStockUnitsAndPerformanceSharesMember2024-09-300001551152us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001551152abbv:DividendDeclared10.26.2023Member2023-10-012023-12-310001551152abbv:DividendDeclared09.06.24Member2024-07-012024-09-300001551152abbv:DividendDeclared09.08.2023Member2023-07-012023-09-300001551152abbv:DividendDeclared06.21.24Member2024-04-012024-06-300001551152abbv:DividendDeclared06.22.2023Member2023-04-012023-06-300001551152abbv:DividendDeclared02.15.2024Member2024-01-012024-03-310001551152abbv:DividendDeclared02.16.23Member2023-01-012023-03-310001551152abbv:December2018StockRepurchaseAuthorizationMember2023-02-160001551152abbv:December2018StockRepurchaseAuthorizationMember2024-01-012024-09-300001551152abbv:December2018StockRepurchaseAuthorizationMember2023-01-012023-09-300001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2023-12-310001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-12-310001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-01-012024-09-300001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2024-01-012024-09-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-01-012024-09-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-01-012024-09-300001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-01-012024-09-300001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-09-300001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2024-09-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-09-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-09-300001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-09-300001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2022-12-310001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-12-310001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-01-012023-09-300001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2023-01-012023-09-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-01-012023-09-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-01-012023-09-300001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-01-012023-09-300001551152us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-09-300001551152abbv:AccumulatedNetGainLossFromNetInvestmentHedgesMember2023-09-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-09-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-09-300001551152us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-09-300001551152us-gaap:NetInvestmentHedgingMemberus-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001551152us-gaap:NetInvestmentHedgingMemberus-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001551152us-gaap:NetInvestmentHedgingMemberus-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001551152us-gaap:NetInvestmentHedgingMemberus-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-07-012024-09-300001551152us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-07-012023-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001551152us-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001551152us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001551152us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001551152us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001551152us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001551152abbv:CrossCurrencySwapContractMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001551152abbv:CrossCurrencySwapContractMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001551152abbv:CrossCurrencySwapContractMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001551152abbv:CrossCurrencySwapContractMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001551152us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001551152us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300001551152abbv:NiaspanMember2024-01-012024-09-300001551152abbv:AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember2019-08-012019-08-310001551152abbv:PrescriptionDrugAbuseLitigationMember2024-09-300001551152abbv:PrescriptionDrugAbuseLitigationInStateCourtsMember2024-09-300001551152abbv:PrescriptionDrugAbuseLitigationBroughtByStatesCountiesCitiesAndOtherMunicipalEntitiesMember2024-09-300001551152abbv:PrescriptionDrugAbuseLitigationInStateCourtsInProcessOfBeingDismissedMember2024-09-300001551152abbv:PrescriptionDrugAbuseLitigationCoveredByAProposedClassSettlementMember2024-09-300001551152abbv:TaxCourtPetitionMember2023-01-012023-09-300001551152abbv:ProductLiabilityALCLLitigationMember2024-09-300001551152abbv:ProductLiabilityOtherLitigationMember2024-09-300001551152abbv:ProductLiabilityALCLLitigationInStateCourtMember2024-09-300001551152abbv:ProductLiabilityOtherLitigationInStateCourtMember2024-09-300001551152abbv:ProductLiabilityALCLLitigationInOtherCountriesMember2024-09-300001551152abbv:ProductLiabilityOtherLitigationInOtherCountriesMember2024-09-300001551152country:USabbv:ImmunologyMemberabbv:HUMIRAMember2024-07-012024-09-300001551152country:USabbv:ImmunologyMemberabbv:HUMIRAMember2023-07-012023-09-300001551152country:USabbv:ImmunologyMemberabbv:HUMIRAMember2024-01-012024-09-300001551152country:USabbv:ImmunologyMemberabbv:HUMIRAMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:ImmunologyMemberabbv:HUMIRAMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:ImmunologyMemberabbv:HUMIRAMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:ImmunologyMemberabbv:HUMIRAMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:ImmunologyMemberabbv:HUMIRAMember2023-01-012023-09-300001551152abbv:ImmunologyMemberabbv:HUMIRAMember2024-07-012024-09-300001551152abbv:ImmunologyMemberabbv:HUMIRAMember2023-07-012023-09-300001551152abbv:ImmunologyMemberabbv:HUMIRAMember2024-01-012024-09-300001551152abbv:ImmunologyMemberabbv:HUMIRAMember2023-01-012023-09-300001551152country:USabbv:ImmunologyMemberabbv:SKYRIZIMember2024-07-012024-09-300001551152country:USabbv:ImmunologyMemberabbv:SKYRIZIMember2023-07-012023-09-300001551152country:USabbv:ImmunologyMemberabbv:SKYRIZIMember2024-01-012024-09-300001551152country:USabbv:ImmunologyMemberabbv:SKYRIZIMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:ImmunologyMemberabbv:SKYRIZIMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:ImmunologyMemberabbv:SKYRIZIMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:ImmunologyMemberabbv:SKYRIZIMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:ImmunologyMemberabbv:SKYRIZIMember2023-01-012023-09-300001551152abbv:ImmunologyMemberabbv:SKYRIZIMember2024-07-012024-09-300001551152abbv:ImmunologyMemberabbv:SKYRIZIMember2023-07-012023-09-300001551152abbv:ImmunologyMemberabbv:SKYRIZIMember2024-01-012024-09-300001551152abbv:ImmunologyMemberabbv:SKYRIZIMember2023-01-012023-09-300001551152country:USabbv:ImmunologyMemberabbv:RINVOQMember2024-07-012024-09-300001551152country:USabbv:ImmunologyMemberabbv:RINVOQMember2023-07-012023-09-300001551152country:USabbv:ImmunologyMemberabbv:RINVOQMember2024-01-012024-09-300001551152country:USabbv:ImmunologyMemberabbv:RINVOQMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:ImmunologyMemberabbv:RINVOQMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:ImmunologyMemberabbv:RINVOQMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:ImmunologyMemberabbv:RINVOQMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:ImmunologyMemberabbv:RINVOQMember2023-01-012023-09-300001551152abbv:ImmunologyMemberabbv:RINVOQMember2024-07-012024-09-300001551152abbv:ImmunologyMemberabbv:RINVOQMember2023-07-012023-09-300001551152abbv:ImmunologyMemberabbv:RINVOQMember2024-01-012024-09-300001551152abbv:ImmunologyMemberabbv:RINVOQMember2023-01-012023-09-300001551152country:USabbv:HematologicOncologyMemberabbv:ImbruvicaMember2024-07-012024-09-300001551152country:USabbv:HematologicOncologyMemberabbv:ImbruvicaMember2023-07-012023-09-300001551152country:USabbv:HematologicOncologyMemberabbv:ImbruvicaMember2024-01-012024-09-300001551152country:USabbv:HematologicOncologyMemberabbv:ImbruvicaMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:HematologicOncologyMemberabbv:ImbruvicaMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:HematologicOncologyMemberabbv:ImbruvicaMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:HematologicOncologyMemberabbv:ImbruvicaMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:HematologicOncologyMemberabbv:ImbruvicaMember2023-01-012023-09-300001551152abbv:HematologicOncologyMemberabbv:ImbruvicaMember2024-07-012024-09-300001551152abbv:HematologicOncologyMemberabbv:ImbruvicaMember2023-07-012023-09-300001551152abbv:HematologicOncologyMemberabbv:ImbruvicaMember2024-01-012024-09-300001551152abbv:HematologicOncologyMemberabbv:ImbruvicaMember2023-01-012023-09-300001551152country:USabbv:HematologicOncologyMemberabbv:VENCLEXTAMember2024-07-012024-09-300001551152country:USabbv:HematologicOncologyMemberabbv:VENCLEXTAMember2023-07-012023-09-300001551152country:USabbv:HematologicOncologyMemberabbv:VENCLEXTAMember2024-01-012024-09-300001551152country:USabbv:HematologicOncologyMemberabbv:VENCLEXTAMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:HematologicOncologyMemberabbv:VENCLEXTAMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:HematologicOncologyMemberabbv:VENCLEXTAMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:HematologicOncologyMemberabbv:VENCLEXTAMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:HematologicOncologyMemberabbv:VENCLEXTAMember2023-01-012023-09-300001551152abbv:HematologicOncologyMemberabbv:VENCLEXTAMember2024-07-012024-09-300001551152abbv:HematologicOncologyMemberabbv:VENCLEXTAMember2023-07-012023-09-300001551152abbv:HematologicOncologyMemberabbv:VENCLEXTAMember2024-01-012024-09-300001551152abbv:HematologicOncologyMemberabbv:VENCLEXTAMember2023-01-012023-09-300001551152country:USabbv:HematologicOncologyMemberabbv:ElahereMember2024-07-012024-09-300001551152country:USabbv:HematologicOncologyMemberabbv:ElahereMember2023-07-012023-09-300001551152country:USabbv:HematologicOncologyMemberabbv:ElahereMember2024-01-012024-09-300001551152country:USabbv:HematologicOncologyMemberabbv:ElahereMember2023-01-012023-09-300001551152abbv:HematologicOncologyMemberabbv:EpkinlyMember2024-07-012024-09-300001551152abbv:HematologicOncologyMemberabbv:EpkinlyMember2023-07-012023-09-300001551152abbv:HematologicOncologyMemberabbv:EpkinlyMember2024-01-012024-09-300001551152abbv:HematologicOncologyMemberabbv:EpkinlyMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:HematologicOncologyMemberabbv:EpkinlyMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:HematologicOncologyMemberabbv:EpkinlyMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:HematologicOncologyMemberabbv:EpkinlyMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:HematologicOncologyMemberabbv:EpkinlyMember2023-01-012023-09-300001551152country:USabbv:AestheticsMemberabbv:BotoxCosmeticMember2024-07-012024-09-300001551152country:USabbv:AestheticsMemberabbv:BotoxCosmeticMember2023-07-012023-09-300001551152country:USabbv:AestheticsMemberabbv:BotoxCosmeticMember2024-01-012024-09-300001551152country:USabbv:AestheticsMemberabbv:BotoxCosmeticMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:AestheticsMemberabbv:BotoxCosmeticMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:AestheticsMemberabbv:BotoxCosmeticMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:AestheticsMemberabbv:BotoxCosmeticMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:AestheticsMemberabbv:BotoxCosmeticMember2023-01-012023-09-300001551152abbv:AestheticsMemberabbv:BotoxCosmeticMember2024-07-012024-09-300001551152abbv:AestheticsMemberabbv:BotoxCosmeticMember2023-07-012023-09-300001551152abbv:AestheticsMemberabbv:BotoxCosmeticMember2024-01-012024-09-300001551152abbv:AestheticsMemberabbv:BotoxCosmeticMember2023-01-012023-09-300001551152country:USabbv:AestheticsMemberabbv:JuvedermCollectionMember2024-07-012024-09-300001551152country:USabbv:AestheticsMemberabbv:JuvedermCollectionMember2023-07-012023-09-300001551152country:USabbv:AestheticsMemberabbv:JuvedermCollectionMember2024-01-012024-09-300001551152country:USabbv:AestheticsMemberabbv:JuvedermCollectionMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:AestheticsMemberabbv:JuvedermCollectionMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:AestheticsMemberabbv:JuvedermCollectionMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:AestheticsMemberabbv:JuvedermCollectionMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:AestheticsMemberabbv:JuvedermCollectionMember2023-01-012023-09-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMember2024-07-012024-09-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMember2023-07-012023-09-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMember2024-01-012024-09-300001551152abbv:AestheticsMemberabbv:JuvedermCollectionMember2023-01-012023-09-300001551152country:USabbv:AestheticsMemberabbv:OtherAestheticsMember2024-07-012024-09-300001551152country:USabbv:AestheticsMemberabbv:OtherAestheticsMember2023-07-012023-09-300001551152country:USabbv:AestheticsMemberabbv:OtherAestheticsMember2024-01-012024-09-300001551152country:USabbv:AestheticsMemberabbv:OtherAestheticsMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:AestheticsMemberabbv:OtherAestheticsMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:AestheticsMemberabbv:OtherAestheticsMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:AestheticsMemberabbv:OtherAestheticsMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:AestheticsMemberabbv:OtherAestheticsMember2023-01-012023-09-300001551152abbv:AestheticsMemberabbv:OtherAestheticsMember2024-07-012024-09-300001551152abbv:AestheticsMemberabbv:OtherAestheticsMember2023-07-012023-09-300001551152abbv:AestheticsMemberabbv:OtherAestheticsMember2024-01-012024-09-300001551152abbv:AestheticsMemberabbv:OtherAestheticsMember2023-01-012023-09-300001551152country:USabbv:NeuroscienceMemberabbv:BotoxTherapeuticMember2024-07-012024-09-300001551152country:USabbv:NeuroscienceMemberabbv:BotoxTherapeuticMember2023-07-012023-09-300001551152country:USabbv:NeuroscienceMemberabbv:BotoxTherapeuticMember2024-01-012024-09-300001551152country:USabbv:NeuroscienceMemberabbv:BotoxTherapeuticMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:BotoxTherapeuticMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:BotoxTherapeuticMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:BotoxTherapeuticMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:BotoxTherapeuticMember2023-01-012023-09-300001551152abbv:NeuroscienceMemberabbv:BotoxTherapeuticMember2024-07-012024-09-300001551152abbv:NeuroscienceMemberabbv:BotoxTherapeuticMember2023-07-012023-09-300001551152abbv:NeuroscienceMemberabbv:BotoxTherapeuticMember2024-01-012024-09-300001551152abbv:NeuroscienceMemberabbv:BotoxTherapeuticMember2023-01-012023-09-300001551152country:USabbv:NeuroscienceMemberabbv:VraylarMember2024-07-012024-09-300001551152country:USabbv:NeuroscienceMemberabbv:VraylarMember2023-07-012023-09-300001551152country:USabbv:NeuroscienceMemberabbv:VraylarMember2024-01-012024-09-300001551152country:USabbv:NeuroscienceMemberabbv:VraylarMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:VraylarMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:VraylarMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:VraylarMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:VraylarMember2023-01-012023-09-300001551152abbv:NeuroscienceMemberabbv:VraylarMember2024-07-012024-09-300001551152abbv:NeuroscienceMemberabbv:VraylarMember2023-07-012023-09-300001551152abbv:NeuroscienceMemberabbv:VraylarMember2024-01-012024-09-300001551152abbv:NeuroscienceMemberabbv:VraylarMember2023-01-012023-09-300001551152country:USabbv:NeuroscienceMemberabbv:DuodopaMember2024-07-012024-09-300001551152country:USabbv:NeuroscienceMemberabbv:DuodopaMember2023-07-012023-09-300001551152country:USabbv:NeuroscienceMemberabbv:DuodopaMember2024-01-012024-09-300001551152country:USabbv:NeuroscienceMemberabbv:DuodopaMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:DuodopaMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:DuodopaMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:DuodopaMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:DuodopaMember2023-01-012023-09-300001551152abbv:NeuroscienceMemberabbv:DuodopaMember2024-07-012024-09-300001551152abbv:NeuroscienceMemberabbv:DuodopaMember2023-07-012023-09-300001551152abbv:NeuroscienceMemberabbv:DuodopaMember2024-01-012024-09-300001551152abbv:NeuroscienceMemberabbv:DuodopaMember2023-01-012023-09-300001551152country:USabbv:NeuroscienceMemberabbv:UbrelvyMember2024-07-012024-09-300001551152country:USabbv:NeuroscienceMemberabbv:UbrelvyMember2023-07-012023-09-300001551152country:USabbv:NeuroscienceMemberabbv:UbrelvyMember2024-01-012024-09-300001551152country:USabbv:NeuroscienceMemberabbv:UbrelvyMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:UbrelvyMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:UbrelvyMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:UbrelvyMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:UbrelvyMember2023-01-012023-09-300001551152abbv:NeuroscienceMemberabbv:UbrelvyMember2024-07-012024-09-300001551152abbv:NeuroscienceMemberabbv:UbrelvyMember2023-07-012023-09-300001551152abbv:NeuroscienceMemberabbv:UbrelvyMember2024-01-012024-09-300001551152abbv:NeuroscienceMemberabbv:UbrelvyMember2023-01-012023-09-300001551152country:USabbv:NeuroscienceMemberabbv:QuliptaMember2024-07-012024-09-300001551152country:USabbv:NeuroscienceMemberabbv:QuliptaMember2023-07-012023-09-300001551152country:USabbv:NeuroscienceMemberabbv:QuliptaMember2024-01-012024-09-300001551152country:USabbv:NeuroscienceMemberabbv:QuliptaMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:QuliptaMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:QuliptaMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:QuliptaMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:QuliptaMember2023-01-012023-09-300001551152abbv:NeuroscienceMemberabbv:QuliptaMember2024-07-012024-09-300001551152abbv:NeuroscienceMemberabbv:QuliptaMember2023-07-012023-09-300001551152abbv:NeuroscienceMemberabbv:QuliptaMember2024-01-012024-09-300001551152abbv:NeuroscienceMemberabbv:QuliptaMember2023-01-012023-09-300001551152country:USabbv:NeuroscienceMemberabbv:OtherNeuroscienceMember2024-07-012024-09-300001551152country:USabbv:NeuroscienceMemberabbv:OtherNeuroscienceMember2023-07-012023-09-300001551152country:USabbv:NeuroscienceMemberabbv:OtherNeuroscienceMember2024-01-012024-09-300001551152country:USabbv:NeuroscienceMemberabbv:OtherNeuroscienceMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:OtherNeuroscienceMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:OtherNeuroscienceMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:OtherNeuroscienceMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:NeuroscienceMemberabbv:OtherNeuroscienceMember2023-01-012023-09-300001551152abbv:NeuroscienceMemberabbv:OtherNeuroscienceMember2024-07-012024-09-300001551152abbv:NeuroscienceMemberabbv:OtherNeuroscienceMember2023-07-012023-09-300001551152abbv:NeuroscienceMemberabbv:OtherNeuroscienceMember2024-01-012024-09-300001551152abbv:NeuroscienceMemberabbv:OtherNeuroscienceMember2023-01-012023-09-300001551152country:USabbv:EyeCareMemberabbv:OzurdexMember2024-07-012024-09-300001551152country:USabbv:EyeCareMemberabbv:OzurdexMember2023-07-012023-09-300001551152country:USabbv:EyeCareMemberabbv:OzurdexMember2024-01-012024-09-300001551152country:USabbv:EyeCareMemberabbv:OzurdexMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:OzurdexMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:OzurdexMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:OzurdexMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:OzurdexMember2023-01-012023-09-300001551152abbv:EyeCareMemberabbv:OzurdexMember2024-07-012024-09-300001551152abbv:EyeCareMemberabbv:OzurdexMember2023-07-012023-09-300001551152abbv:EyeCareMemberabbv:OzurdexMember2024-01-012024-09-300001551152abbv:EyeCareMemberabbv:OzurdexMember2023-01-012023-09-300001551152country:USabbv:EyeCareMemberabbv:LumiganGanfortMember2024-07-012024-09-300001551152country:USabbv:EyeCareMemberabbv:LumiganGanfortMember2023-07-012023-09-300001551152country:USabbv:EyeCareMemberabbv:LumiganGanfortMember2024-01-012024-09-300001551152country:USabbv:EyeCareMemberabbv:LumiganGanfortMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:LumiganGanfortMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:LumiganGanfortMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:LumiganGanfortMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:LumiganGanfortMember2023-01-012023-09-300001551152abbv:EyeCareMemberabbv:LumiganGanfortMember2024-07-012024-09-300001551152abbv:EyeCareMemberabbv:LumiganGanfortMember2023-07-012023-09-300001551152abbv:EyeCareMemberabbv:LumiganGanfortMember2024-01-012024-09-300001551152abbv:EyeCareMemberabbv:LumiganGanfortMember2023-01-012023-09-300001551152country:USabbv:EyeCareMemberabbv:AlphaganCombiganMember2024-07-012024-09-300001551152country:USabbv:EyeCareMemberabbv:AlphaganCombiganMember2023-07-012023-09-300001551152country:USabbv:EyeCareMemberabbv:AlphaganCombiganMember2024-01-012024-09-300001551152country:USabbv:EyeCareMemberabbv:AlphaganCombiganMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:AlphaganCombiganMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:AlphaganCombiganMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:AlphaganCombiganMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:AlphaganCombiganMember2023-01-012023-09-300001551152abbv:EyeCareMemberabbv:AlphaganCombiganMember2024-07-012024-09-300001551152abbv:EyeCareMemberabbv:AlphaganCombiganMember2023-07-012023-09-300001551152abbv:EyeCareMemberabbv:AlphaganCombiganMember2024-01-012024-09-300001551152abbv:EyeCareMemberabbv:AlphaganCombiganMember2023-01-012023-09-300001551152country:USabbv:EyeCareMemberabbv:RestasisMember2024-07-012024-09-300001551152country:USabbv:EyeCareMemberabbv:RestasisMember2023-07-012023-09-300001551152country:USabbv:EyeCareMemberabbv:RestasisMember2024-01-012024-09-300001551152country:USabbv:EyeCareMemberabbv:RestasisMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:RestasisMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:RestasisMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:RestasisMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:RestasisMember2023-01-012023-09-300001551152abbv:EyeCareMemberabbv:RestasisMember2024-07-012024-09-300001551152abbv:EyeCareMemberabbv:RestasisMember2023-07-012023-09-300001551152abbv:EyeCareMemberabbv:RestasisMember2024-01-012024-09-300001551152abbv:EyeCareMemberabbv:RestasisMember2023-01-012023-09-300001551152country:USabbv:EyeCareMemberabbv:OtherEyeCareMember2024-07-012024-09-300001551152country:USabbv:EyeCareMemberabbv:OtherEyeCareMember2023-07-012023-09-300001551152country:USabbv:EyeCareMemberabbv:OtherEyeCareMember2024-01-012024-09-300001551152country:USabbv:EyeCareMemberabbv:OtherEyeCareMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:OtherEyeCareMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:OtherEyeCareMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:OtherEyeCareMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:EyeCareMemberabbv:OtherEyeCareMember2023-01-012023-09-300001551152abbv:EyeCareMemberabbv:OtherEyeCareMember2024-07-012024-09-300001551152abbv:EyeCareMemberabbv:OtherEyeCareMember2023-07-012023-09-300001551152abbv:EyeCareMemberabbv:OtherEyeCareMember2024-01-012024-09-300001551152abbv:EyeCareMemberabbv:OtherEyeCareMember2023-01-012023-09-300001551152country:USabbv:OtherKeyProductsMemberabbv:MAVYRETMember2024-07-012024-09-300001551152country:USabbv:OtherKeyProductsMemberabbv:MAVYRETMember2023-07-012023-09-300001551152country:USabbv:OtherKeyProductsMemberabbv:MAVYRETMember2024-01-012024-09-300001551152country:USabbv:OtherKeyProductsMemberabbv:MAVYRETMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:OtherKeyProductsMemberabbv:MAVYRETMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:OtherKeyProductsMemberabbv:MAVYRETMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:OtherKeyProductsMemberabbv:MAVYRETMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:OtherKeyProductsMemberabbv:MAVYRETMember2023-01-012023-09-300001551152abbv:OtherKeyProductsMemberabbv:MAVYRETMember2024-07-012024-09-300001551152abbv:OtherKeyProductsMemberabbv:MAVYRETMember2023-07-012023-09-300001551152abbv:OtherKeyProductsMemberabbv:MAVYRETMember2024-01-012024-09-300001551152abbv:OtherKeyProductsMemberabbv:MAVYRETMember2023-01-012023-09-300001551152country:USabbv:OtherKeyProductsMemberabbv:CreonMember2024-07-012024-09-300001551152country:USabbv:OtherKeyProductsMemberabbv:CreonMember2023-07-012023-09-300001551152country:USabbv:OtherKeyProductsMemberabbv:CreonMember2024-01-012024-09-300001551152country:USabbv:OtherKeyProductsMemberabbv:CreonMember2023-01-012023-09-300001551152country:USabbv:OtherKeyProductsMemberabbv:LinzessConstellaMember2024-07-012024-09-300001551152country:USabbv:OtherKeyProductsMemberabbv:LinzessConstellaMember2023-07-012023-09-300001551152country:USabbv:OtherKeyProductsMemberabbv:LinzessConstellaMember2024-01-012024-09-300001551152country:USabbv:OtherKeyProductsMemberabbv:LinzessConstellaMember2023-01-012023-09-300001551152us-gaap:NonUsMemberabbv:OtherKeyProductsMemberabbv:LinzessConstellaMember2024-07-012024-09-300001551152us-gaap:NonUsMemberabbv:OtherKeyProductsMemberabbv:LinzessConstellaMember2023-07-012023-09-300001551152us-gaap:NonUsMemberabbv:OtherKeyProductsMemberabbv:LinzessConstellaMember2024-01-012024-09-300001551152us-gaap:NonUsMemberabbv:OtherKeyProductsMemberabbv:LinzessConstellaMember2023-01-012023-09-300001551152abbv:OtherKeyProductsMemberabbv:LinzessConstellaMember2024-07-012024-09-300001551152abbv:OtherKeyProductsMemberabbv:LinzessConstellaMember2023-07-012023-09-300001551152abbv:OtherKeyProductsMemberabbv:LinzessConstellaMember2024-01-012024-09-300001551152abbv:OtherKeyProductsMemberabbv:LinzessConstellaMember2023-01-012023-09-300001551152abbv:OtherProductsMember2024-07-012024-09-300001551152abbv:OtherProductsMember2023-07-012023-09-300001551152abbv:OtherProductsMember2024-01-012024-09-300001551152abbv:OtherProductsMember2023-01-012023-09-30

美国
证券交易委员会
华盛顿特区20549
表格10-Q
（标记一）
☒季度报告根据1934年证券交易所法案第13或第15(d)条款
截至季度结束日期的财务报告2024年9月30日
或者
☐过渡报告根据1934年证券交易所法案第13或第15(d)条款
在过渡期内                                   到                                   
委员会备案号码：001-35565
abbvieimage1a54.jpg
雅培制药公司
(根据其章程规定的注册人准确名称)
特拉华州
32-0375147
（设立或组织的其他管辖区域）
(国税局雇主识别号)
北咏根路1号
North Chicago, 伊利诺伊州 60064-6400
电话：(847) 932-7900
请用勾号表示以下内容（1）在过去12个月内（或注册者需要提交此类报告的更短时间内），已提交《证券交易法》第13条或第15（d）条所述的所有报告，（2）在过去90 日内遵守此类提交要求。是 ☒ 没有 ☐
请在复选框中指出公司是否在过去12个月内（或者公司需提交这些文件的较短期间内）按照Regulation S-t的规则（本章节第232.405条）电子提交了每一个交互数据文件。是 ☒ 没有 ☐
请在复选框内打勾，表示注册人是大型加速报告人、加速报告人、非加速报告人、小型报告公司或新兴成长型企业。关于“大型加速报告人”、“加速报告人”、“小型报告公司”和“新兴成长型企业”的定义，请参见证券交易法120亿.2条规定。
大型加速存取器
☒加速存取器☐
非大型快速提交者☐较小的报告公司☐
新兴成长公司☐
如果是新兴成长型企业，请勾选复选标记，表明注册者已选择不使用延长过渡期来符合根据证券交易法第13(a)条规定提供的任何新财务会计准则。 ☐
在对号处打勾表示公司是否为壳公司（按照《证券交易法》规定第120亿.2条定义）。是的 ☐ 否 ☒
在法案第12(b)条的规定下注册的证券：
每个课程的标题交易符号注册的每个交易所的名称
普通股，面值每股0.01美元ABBV纽约证券交易所
芝加哥证券交易所
0.750% 2027 年到期的优先票据ABBV27纽约证券交易所
2.125% 2028年到期的优先票据ABBV28纽约证券交易所
2.625% 2028年到期的优先票据ABBV28B纽约证券交易所
2.125% 2029年到期的优先票据ABBV29纽约证券交易所
1.250% 2031年到期的优先票据ABBV31纽约证券交易所
截至2024年10月28日，AbbVie Inc.拥有 1,767,140,323 每股面值为0.01美元的普通股共计1766343745股。


AbbVie公司和子公司
目录

页面



第一部分. 财务信息
项目1。 基本报表和补充数据
AbbVie公司和子公司
汇编财务报表（未经审计）

三个月结束了
九月三十日		九个月已结束
九月三十日
（以百万计，每股数据除外）2024202320242023
净收入$14,460 $13,927 $41,232 $40,017 
销售产品的成本4,212 6,485 12,508 14,711 
销售、一般和管理4,205 3,372 10,897 9,679 
研究和开发2,130 1,723 6,017 5,748 
收购了IPR&D和里程碑82 66 1,183 496 
其他营业收入— — — (179)
运营成本和支出总额10,629 11,646 30,605 30,455 
营业收益3,831 2,281 10,627 9,562 
利息支出，净额591 398 1,550 1,306 
净外汇损失（收益）(3)25 2 97 
其他支出（收入），净额1,159 (95)3,090 3,121 
所得税支出前的收益2,084 1,953 5,985 5,038 
所得税支出520 172 1,676 989 
净收益1,564 1,781 4,309 4,049 
归属于非控股权益的净收益3 3 9 8 
归属于艾伯维公司的净收益$1,561 $1,778 $4,300 $4,041 
每股数据
归属于艾伯维公司的每股基本收益$0.88 $1.00 $2.41 $2.27 
归属于艾伯维公司的摊薄后每股收益$0.88 $1.00 $2.41 $2.26 
已发行基本股的加权平均值1,769 1,767 1,769 1,768 
加权平均摊薄后已发行股票1,772 1,771 1,772 1,772 

随附说明是这些简明合并财务报表的一部分。
2024年第三季度报表 | abbvieimage2a21.gif
1

AbbVie公司和其子公司
简明综合收益表（未经审计）
截至三个月结束时
2020年9月30日		截至九月底的九个月的营业租赁成本
2020年9月30日
（以百万计）2024202320242023
净收益$1,564 $1,781 $4,309 $4,049 
外币翻译调整，税后费用（益）$25 三个月和$1 截至2024年9月30日的九个月和$17三个月和$的六个月截至2023年6月30日$(11）截至2023年9月30日的九个月
574 (457)21 (279)
净投资套期保值活动，税后费用（收益）为$91三个月和$的六个月截至2023年6月30日$(11）截至2024年9月30日的九个月和$84 三个月和$26 ）截至2023年9月30日的九个月
(330)302 (39)89 
养老金和离职后福利净额（税前），为2024年9月30日结束的九个月为$(1三个月和$3 ，截至2024年9月30日结束的九个月为$1 三个月和$11 ，截至2023年9月30日结束的九个月为$
(3)2 15 38 
现金流量套期保值活动，净税费收益/费用为$(8三个月和$的六个月截至2023年6月30日$(3，截至2024年9月30日结束的九个月为$7 )。1截至2023年9月30日的九个月
(62)52 (26)(2)
其他综合收益（损失）179 (101)(29)(154)
综合收益1,743 1,680 4,280 3,895 
归属于非控股股东的综合收益3 3 9 8 
归属于艾伯维公司的综合收益。$1,740 $1,677 $4,271 $3,887 

随附说明是这些简明合并财务报表的一部分。



2024年第三季度报表 | abbvieimage2a21.gif
2

AbbVie公司和其子公司
汇编的综合资产负债表
（以百万计，股份数据除外）2020年9月30日
2024		截至12月31日公允价值
2023
(未经审计)
资产
流动资产
现金及现金等价物$7,257 $12,814 
短期投资28 2 
2,687,823 11,472 11,155 
存货4,450 4,099 
预付费用和其他4,578 4,932 
总流动资产27,785 33,002 
投资267 304 
资产和设备，净值5,141 4,989 
无形资产, 净额66,646 55,610 
商誉35,295 32,293 
其他8,288 8,513 
总资产$143,422 $134,711 
负债和股东权益
流动负债
长期债务及融资租赁负债的本期部分$12,570 $7,191 
应付账款及应计费用30,492 30,650 
流动负债合计43,062 37,841 
长期负债和融资租赁负债58,509 52,194 
延迟所得税2,749 1,952 
其他长期负债33,031 32,327 
承诺和 contingencies
股东权益
普通股，每股面值为 $0.0001；0.01每股面值，4,000,000,000 1,831,415,039 截至2024年9月30日，已发行股份 1,823,046,087截至2023年12月31日
18 18 
截至2024年6月30日，公司已回购普通股64,283,710股，成本为 64,310,426 截至2024年9月30日的股份和 57,105,354截至2023年12月31日
(7,848)(6,533)
额外实收资本21,160 20,180 
累积赤字(4,964)(1,000)
累计其他综合损失(2,334)(2,305)
股东权益合计6,032 10,360 
非控股权益39 37 
股东权益总计6,071 10,397 
负债和所有者权益总额$143,422 $134,711 
附注是这些简明合并财务报表的组成部分。
2024年第三季度报表 | abbvieimage2a21.gif
3

AbbVie公司和其子公司
未经审计的综合股本报表

（单位百万）普通股股份数 自家保管的股票额外实收资本1,102.0累计其他综合损失非控股权益总计
2023年6月30日的余额1,765 $18 $(6,528)$19,839 $1,789 $(2,252)$32 $12,898 
AbbVie公司归属于母公司的净收益。— — — — 1,778 — — 1,778 
其他综合损失，净额— — — — — (101)— (101)
3,341,700— — — — (2,634)— — (2,634)
购买公司股票— — (4)— — — — (4)
股票补偿计划和其他— — 7 182 — — — 189 
非控股权益变动— — — — — — 3 3 
2023年9月30日结余1,765 $18 $(6,525)$20,021 $933 $(2,353)$35 $12,129 
2024年6月30日余额1,766 $18 $(7,838)$20,879 $(3,768)$(2,513)$43 $6,821 
净利润归属于AbbVie Inc。— — — — 1,561 — — 1,561 
其他综合收益，扣除税后— — — — — 179 — 179 
3,341,700— — — — (2,757)— — (2,757)
购买公司股票— — (17)— — — — (17)
股票补偿计划和其他1 — 7 281 — — — 288 
非控股权益变动— — — — — — (4)(4)
2024年9月30日的余额1,767 $18 $(7,848)$21,160 $(4,964)$(2,334)$39 $6,071 
2022年12月31日结存余额1,769 $18 $(4,594)$19,245 $4,784 $(2,199)$33 $17,287 
净利润归属于AbbVie Inc。— — — — 4,041 — — 4,041 
其他综合损失，净额— — — — — (154)— (154)
3,341,700— — — — (7,892)— — (7,892)
购买公司股票(12)— (1,969)— — — — (1,969)
股票激励计划和其他8 — 38 776 — — — 814 
非控股权益变动— — — — — — 2 2 
2023年9月30日结余1,765 $18 $(6,525)$20,021 $933 $(2,353)$35 $12,129 
2023年12月31日结余为1,766 $18 $(6,533)$20,180 $(1,000)$(2,305)$37 $10,397 
阿比维公司可归属于净收益— — — — 4,300 — — 4,300 
其他综合损失，净额— — — — — (29)— (29)
3,341,700— — — — (8,264)— — (8,264)
购买公司股票(7)— (1,350)— — — — (1,350)
按股票补偿计划和其他8 — 35 980 — — — 1,015 
非控股权益变动— — — — — — 2 2 
2024年9月30日的余额1,767 $18 $(7,848)$21,160 $(4,964)$(2,334)$39 $6,071 

The accompanying notes are an integral part of these condensed consolidated financial statements.
2024 Form 10-Q | abbvieimage2a21.gif
4

AbbVie公司和子公司
压缩的现金流量表（未经审计）
九个月结束
September 30,
（以百万为单位）（括号表示现金流出）20242023
经营活动现金流
净收益$4,309 $4,049 
调整净收益以便与经营活动产生的现金流量调节：
折旧558 565 
无形资产摊销5,726 6,057 
延迟所得税(682)(1,498)
变动的应计可变偿付额负债的公允价值3,492 3,432 
偿付应计负债(1,456)(407)
股票补偿747 622 
已获得知识产权和里程碑1,183 496 
非现金诉讼准备调整（扣除现金支付）341 (205)
无形资产减值损失— 2,824 
其他，净额(75)(219)
运营资产和负债的变动，净额，除收购
应收账款(180)(273)
存货(191)(513)
预付款项和其他资产461 394 
应付账款和其他负债(1,070)3,661 
所得税资产和负债净额(1,405)(899)
经营活动现金流11,758 18,086 
投资活动现金流量
收购企业，净额(17,493)— 
其他收购和投资(1,232)(670)
物业和设备的收购(683)(572)
投资证券购买(46)(43)
投资证券的销售和到期516 41 
其他，净额(8)35 
投资活动现金流量(18,946)(1,209)
筹资活动现金流量
发行其他短期借款的收款5,008 — 
偿还其他开空短期借款的付款(5,008)— 
长期债务发行所得14,963 — 
偿还长期债务和融资租赁债务(3,851)(2,355)
债务发行费用(99)— 
分红派息(8,273)(7,913)
购买公司股票(1,350)(1,969)
行使期权所得款项204 149 
支付相关考虑责任的支付— (735)
其他，净额56 50 
筹资活动现金流量1,650 (12,773)
汇率变化对现金和等价物的影响(19)(18)
现金及等价物净变动(5,557)4,086 
现金与现金等价物期初余额12,814 9,201 
现金与现金等价物期末余额$7,257 $13,287 
附注是这些简明合并财务报表的组成部分。
2024年第三季度报表 | abbvieimage2a21.gif
5

AbbVie公司和子公司
简明合并财务报表附注（未经审计）
注释1报告前提
历史陈述的基础
艾伯维公司（AbbVie）未经审计的中期简明合并基本报表已根据美国证券交易委员会的规定和法规编制。因此，根据美国通用会计准则编制的年度财务报表通常包含的某些信息和脚注披露已被省略。这些未经审计的中期简明合并基本报表应与本公司审计的合并财务报表和附注一起阅读，这些报表和附注已包含在本公司2023年度10-K表格的年度报告中。
公司管理层认为，这些基本报表包括了所有正常和周期性调整，以便对公司的财务状况和经营业绩进行公正的呈现。任何中期净收入和净利润并不一定能反映未来或全年的结果。为符合当前期间的呈现，对上期间财务报表进行了某些其他再分类。
艾伯维公司在2024年2月12日和2024年8月1日分别完成了先前宣布的对immunogen公司（immunogen）和cerevel therapeutics holdings公司（cerevel therapeutics）的收购。有关这些收购的详细信息，请参阅附注4和附注8。
最近的会计声明
最近未采纳的会计声明
ASU编号2023-09
2023年12月，财务会计准则委员会（FASB）发布了会计准则更新（ASU）2023-09， 所得税 - 改善所得税披露（主题740）。该准则要求将有效税率调整细分为标准类别，增强所得税支付披露，并修改其他与所得税有关的披露。该准则将从2025年开始对艾伯维公司生效，允许提前采纳。当前，艾伯维公司正在评估采用这项指导对其合并财务报表的影响。
ASU编号2023-07
2023年11月，FASB发布ASU No. 2023-07 分部报告-改进可报告部门披露（主题280）该标准要求披露包括定期提供给首席运营决策者（CODM）的重要部门费用，报告部门的其他项目描述，并在决定如何分配资源时，CODM使用的任何分部利润或亏损的额外衡量。ASU还要求所有年度披露目前要求的主题280在中期也要包含。该标准将于2024年开始对AbbVie的年度期间生效，并于2025年中期生效，允许提前使用并要求对财务报表中显示的所有之前期间进行追溯应用。艾伯维公司目前正在评估采纳此指引对其合并财务报表的影响。
2024年第三季度报表 | abbvieimage2a21.gif
6

注意事项 2 补充财务信息
利息支出，净额
三个月结束了
九月三十日		九个月已经结束
九月三十日
（单位：百万）2024202320242023
利息支出$720 $555 $2,106 $1,660 
利息收入(129)(157)(556)(354)
利息支出，净额$591 $398 $1,550 $1,306 
存货
（以百万计）September 30,
2024		截至12月31日公允价值
2023
成品$1,347 $1,356 
在制品2,071 1,643 
原材料1,032 1,100 
存货$4,450 $4,099 
固定资产，净值
（以百万计）September 30,
2024		截至12月31日公允价值
2023
234,036$12,279 $11,635 
累计折旧(7,138)(6,646)
资产和设备，净值$5,141 $4,989 
折旧费用分别为2024年3月31日和2023年3月31日的美元191 百万美元，截至2023年9月30日为$558 截至2024年9月30日的九个月，利润为XX百万美元196 百万美元，截至2023年9月30日为$565 百万美元。
2024年第三季度报表 | abbvieimage2a21.gif
7

《营收确认，与客户的合同》注释3 每股收益
艾伯维公司授予某些被视为参与证券的受限股票单位（RSUs）。由于存在参与证券，艾伯维公司使用更具稀释性的国库股票或双重分类法计算每股收益（EPS）。在提供的所有时期中，双重分类法较为稀释。
下表总结了双类方法的影响：
截至三个月结束
September 30,		九个月结束
September 30,
（以百万美元为单位，除每股数据外）2024202320242023
每股收益
阿比维公司可归属于净收益$1,561 $1,778 $4,300 $4,041 
分配给优先证券的收益10 11 30 32 
可供普通股股东分配的收益$1,551 $1,767 $4,270 $4,009 
加权平均基本股本数1,769 1,767 1,769 1,768 
AbbVie公司每股基本收益。$0.88 $1.00 $2.41 $2.27 
摊薄后每股收益
阿比维公司可归属于净收益$1,561 $1,778 $4,300 $4,041 
分配给优先股的收益10 11 30 32 
可供普通股东使用的收益$1,551 $1,767 $4,270 $4,009 
普通股加权平均股本1,769 1,767 1,769 1,768 
稀释证券的影响3 4 3 4 
每股加权平均摊薄股数1,772 1,771 1,772 1,772 
AbbVie公司每股摊薄收益。$0.88 $1.00 $2.41 $2.26 
由于效果会对获得股票的补偿计划发行的某些股票产生抵消作用，因此这些股票未计入每股收益的计算。被排除的普通股数量在所有期间均微不足道。
2024年第三季度报表 | abbvieimage2a21.gif
8

注4 许可、收购和其他安排
拟收购Aliada Therapeutics Holdings, Inc。
2024年9月30日之后，2024年10月28日，艾伯维公司宣布已达成一项明确协议，收购了Aliada Therapeutics, Inc.（Aliada），包括其主导项目ALIA-1758。ALIA-1758是一种抗胰岐化鲀类淀粉样蛋白（3pE-Aβ）抗体，用于治疗阿尔茨海默病。根据协议的条款，艾伯维公司将支付约\$1.4现金作为收购Aliada的全部优先股权。拟议交易的完成取决于监管批准和其他惯例的关闭条件。

收购cerevel therapeutics holdings公司。
2024年8月1日，艾伯维公司完成了其先前宣布的对Cerevel Therapeutics的收购。Cerevel Therapeutics是一家临床阶段的生物技术公司，专注于发现和开发用于神经科学疾病的差异化疗法。Cerevel Therapeutics的神经科学管线包括多个临床阶段和临床前候选药物，有潜力治疗包括精神分裂症、帕金森病和情绪障碍在内的多种疾病。根据协议条款，艾伯维公司以每股$收购了所有未流通的Cerevel Therapeutics股票。45.00 现金每股的交易类型为Cerevel Therapeutics普通股的所有者转让的考虑的总公允价值为$（折现1亿美元）。8.7•此外，2020年12月16日，一些州检察官在美国德克萨斯州东区地方法院提起了反垄断诉讼，声称Google在广告技术方面违反了美国反垄断法律以及州欺骗性贸易法律，2025年3月安排了审判。此外，2023年1月24日，司法部和许多州检察官在维吉尼亚州东区地方法院提起了反垄断诉讼，称Google的数字广告技术产品违反了美国反垄断法，2023年4月17日，许多州检察官加入了诉讼。审判安排在2024年9月。欧盟委员会、英国竞争与市场监管局和澳大利亚竞争与消费者委员会分别于2021年6月22日、2022年5月25日和2022年6月29日对Google的广告技术业务实践开展了正式调查。2023年6月14日，欧盟委员会发出反垄断指控（SO），通知Google其初步认为Google在其广告技术方面违反了欧洲反垄断法。我们于2023年12月1日对SO作出了回应。8.3 亿美元。净现金价值包括转让给Cerevel Therapeutics普通股所有者的考虑的总公允价值为$（折现1亿美元）。
收购Cerevel Therapeutics已被记录为一项业务组合，采用会计的收购方法。 收购方法要求在业务组合中获取的资产和承担的负债应当根据收购日期的公允价值确认。 截至2024年9月30日，获取的资产和承担的负债的估值尚未最终确定。 因此，艾伯维公司记录了有关收购日期资产和负债的公允价值的初步估计。 在测量期内完成估值可能导致在收购日期关于无形资产、商誉和所得税的公允价值等项目的金额发生变化。 估值工作将在收购日期之后一年之内完成。
下表汇总了截至收购之日收购资产和承担的负债的初步公允价值：
（单位：百万）
收购的资产和承担的负债
现金及等价物$361 
短期投资382 
预付费用和其他流动资产9 
财产和设备，净额25 
投资121 
无形资产，净额8,100 
其他非流动资产31 
长期债务的当前部分(400)
应付账款和应计负债(100)
长期债务(246)
递延所得税(1,292)
其他长期负债(31)
可识别净资产总额6,960 
善意1,702 
收购的总资产和承担的负债$8,662 
无形资产涉及$8.1 收购过程中的研发支出（IPR&D）金额达数十亿美元，与尚未获得监管批准的产品相关。可识别无形资产的预估公允价值是使用“收入法”确定的，这是一种估值技术，根据市场参与者对资产在其剩余使用寿命内将产生的现金流的预期，提供对资产公允价值的估计。这些资产估值开发中更为重要的假设之一是每年每项资产或产品的预计净现金流，衡量未来现金流量中所固有风险所需的适当折现率，每项资产的生命周期，潜在的监管和商业成功风险，影响资产和每项现金流的竞争趋势，以及其他因素。
2024年第三季度报表 | abbvieimage2a21.gif
9

艾伯维公司承担的长期债务的当前部分为$345 百万美元的总本金 2.52027年到期的可转换高级票据。收购后，可转换高级票据变为可召回，持票人可以以溢价的现金赎回可转换高级票据。截至收购日期，这些可转换高级票据以$的总公允价值被确认为长期债务的当前部分，列入简明合并资产负债表。400 百万美元。收购日期后，公司偿还了可转换高级票据，截至2024年9月30日，没有任何未偿还金额。
艾伯维公司承担的长期债务与收购前Cerevel Therapeutics签订的融资协议有关。根据协议，Cerevel Therapeutics收到资金用于支持tavapadon的开发，并同意根据美国食品药品监督管理局（FDA）批准tavapadon后偿还监管里程碑、销售里程碑和版税。这些资金协议被视为融资安排，相关融资责任的公允价值为$246万美元，截至收购日期。融资责任的预估公允价值是通过概率加权的预期支付模型确定监管里程碑支付，并通过蒙特卡洛模拟模型确定销售里程碑和版税支付，然后按折现值进行折现。公允价值开发中的假设包括折现率、预估概率、里程碑达成时间和未来销售金额的预估。有关更多信息，请参阅附注8。
商誉是按转让考虑超过已确认净资产公允价值的多余部分计算的，代表从无法单独识别并单独确认的其他已获取资产所产生的未来经济利益。特别是，从收购Cerevel Therapeutics中确认的商誉代表了预期的协同效应，包括以下能力：(i)拓展AbbVie的神经科学管线，(ii)利用AbbVie的商业、监管和临床专业知识以最大化Cerevel Therapeutic的资产，以及(iii)增强AbbVie的现有神经科学发现能力。商誉在税务目的上不可抵扣。
艾伯维公司还承接了Cerevel Therapeutics与辉瑞公司(Pfizer)在收购之前签署的许可协议。根据该协议，Cerevel Therapeutics获得了在某些辉瑞专利权下开发、生产和商业化Cerevel Therapeutic项目中包含的化合物的独占全球许可。艾伯维公司可以根据所有项目的某些监管和商业里程碑的达成，进行最多达$的额外付款。1.6此外，艾伯维公司将在净收入上支付分级版税。
收购日期后，Cerevel Therapeutics的运营结果已包括在简明合并基本报表中。从收购日期到2024年9月30日，归因于Cerevel Therapeutics的运营亏损为$299百万美元，其中包括与净投资套期保值相关的$161 百万美元的现金结算、发帖后费用用于给予Cerevel Therapeutics员工的激励奖。AbbVie还根据交易协议中描述的转换因子，向Cerevel Therapeutics股权奖持有人发放了 0.3百万RSUs，与收购协议中描述的转换因子有关。与收购日期发行的RSUs相关的股票补偿费用不重要。
收购相关费用主要包括监管、财务咨询和法律费用，截至2024年6月30日，共计$ million，并计入收入、一般及行政支出 (SG&A) 内的简明合并利润表。44 到2024年9月30日止九个月为xx百万美元，并包括在简式合并利润表的销售、一般和管理费用中。.
收购ImmunoGen公司。
2024年2月12日，艾伯维公司完成了先前宣布收购Immunogen的交易。Immunogen是一家商业生物技术公司，专注于为癌症患者发现、开发和商业化抗体药物结合物（ADC）。Immunogen的肿瘤学产品组合包括其旗舰抗癌治疗Elahere，这是一种首发的ADC，已获批用于铂金耐药性卵巢癌，以及具有潜在前景的针对血液系统恶性肿瘤和实体瘤的下一代ADC。该组合加速了艾伯维公司进入实体肿瘤领域，并增强了其肿瘤学产品管线。根据协议条款，艾伯维以每股88美元的现金收购了Immunogen的全部优先股。对于Immunogen普通股股东转让的合理价值为净现金收购后的58亿美元。31.26 每股88美元现金。用于Immunogen普通股股东转让的合理价值 总共为58亿美元。9.8163.99.258
immunogen的收购已被视为一项采用了会计收购方法的业务组合。在会计收购方法中，业务组合中获得的资产和承担的负债等其他事项必须在收购日期按其公允价值予以确认。截至2024年9月30日，尚未最终确定所获得的资产和承担的负债的估值。因此，艾伯维公司记录了截至收购日期为止所获得的资产和承担的负债的公允价值的初步估计。在计量期内完成估值可能导致在收购日期为无形资产、商誉和所得税的公允价值等其他项目方面记录的金额发生变化。估值将在收购日期后不迟于一年完成。
2024年第三季度报表 | abbvieimage2a21.gif
10

下表汇总了截至收购之日收购资产和承担的负债的初步公允价值：
（单位：百万）
收购的资产和承担的负债
现金及等价物$591 
应收账款171 
库存211 
预付费用和其他流动资产40 
财产和设备，净额7 
无形资产，净额
开发产品版权7,200 
许可协议125 
收购了正在进行的研发1,280 
其他非流动资产273 
长期债务的当前部分(99)
应付账款和应计负债(312)
递延所得税(899)
其他长期负债(47)
可识别净资产总额8,541 
善意1,249 
收购的总资产和承担的负债$9,790 
当存货出售给客户时，衡量账面价值所需的调整，即有效利用的成本，将被分摊到产品销售成本中。该存货的销售预计在收购日后约一年内完成。179在存货销售给客户时，600万将按摊销到销售成本中，预计将在大约从收购日期起的一年内完成。
无形资产涉及$7.3 具有明确有限生命周期的无形资产$十亿和与尚未获得监管批准的产品相关的$十亿已收购的正在进行的研究和开发(IPR＆D)。已收购的具有明确有限生命周期的无形资产包括开发的产品权利和许可协议，按照加权平均预计使用寿命约为1.3 与尚未获得监管批准的产品相关的收购的研发支出为数十亿美元。收购的明确有限生命无形资产包括开发的产品权利和许可协议，并将在约加权平均预计使用寿命期间摊销 12
其他非流动资产主要包括$250递延税款资产100万美元。
艾伯维公司承担的长期债务目前部分已在收购时以公允价值$开多百万的价格偿还。有关详细信息请参见注8。99有关详细信息请参见注8。
商誉是根据认定的净资产公允价值的 excess and consideration 计算的，代表从未能分辨认定而单独认可的其他资产中获得的未来经济效益。具体地，从收购 Immunogen 而确认的商誉代表了预期的协同效应，包括：（i） 扩大 AbbVie 的产品组合以及未来增长平台的收入提高潜力，（ii）加速 AbbVie 在肿瘤学实体肿瘤领域的临床和商业存在，（iii）利用各自公司的优势，（iv）增强 AbbVie 现有的 ADC 开发工作。商誉不可抵扣税收。
在收购日期后，immunogen的运营结果已包含在简明合并基本报表中。截至2024年9月30日的收购日起，可归属于immunogen的净收入为$396 百万美元，归属于Immunogen的净收入为$百万，Immunogen的运营亏损为$百万。582百万美元，其中包括与净投资套期保值相关的$349 归属于Immunogen的现金结算的流程结束费用为$百万。158 库存公允价值调整的摊销为$百万。113 无形资产摊销为$百万。 0.3 AbbVie还根据交易协议向持有Immunogen股权的持有人发行了$百万股份的RSUs，基于一种转换因子。与收购日期发行的RSUs相关的股票补偿费用不显着。
2024年第三季度报表 | abbvieimage2a21.gif
11

收购相关费用主要包括监管、财务咨询和法律费用，截至2024年6月30日，共计$ million，并计入收入、一般及行政支出 (SG&A) 内的简明合并利润表。59 截至2024年9月30日的九个月中，这些支出达到了百万美元，并已计入概括综合收益陈述表中的销售和管理费用。.
Pro Forma财务信息
以下表格展示了艾伯维公司、immunogen和Cerevel Therapeutics截至2024年和2023年9月30日三个月和九个月的未经审计的合并业绩，假设immunogen和Cerevel Therapeutics的收购发生在2023年1月1日：
截至三个月结束
September 30,		九个月结束
September 30,
（单位百万）2024202320242023
净利润$14,460 $14,040 $41,287 $40,263 
净收益1,714 1,400 4,583 2,309 
未经审计的合并财务信息是使用收购会计方法编制的，并基于艾伯维公司、immunogen和Cerevel Therapeutics的历史财务信息。为了反映2023年1月1日收购的发生，未经审计的合并财务信息包括调整，以反映根据获取的可识别无形资产的当前初步公允价值而将发生的增量摊销费用；与收购日库存相关的公允价值调整的产品销售的增量成本；与发行债务以筹资收购相关的额外利息费用；以及将发生在2024年9月30日结束的三个月和九个月内的收购相关成本的重新分类至2023年9月30日结束的九个月。未经审计的合并财务信息不一定表明如果收购于2023年1月1日完成，运营的综合结果将会怎样。此外，未经审计的合并财务信息不是联合公司未来运营结果的预测，并不反映与收购相关的任何协同效应或成本节约的预期实现。
其他许可和收购活动
与其他收购和投资相关的现金流出总额为$。1.2 截至2024年9月30日的前九个月销售额达到亿美元670 百万美元。
下表总结了已获得的IPR&D和里程碑费用：
三个月结束了
九月三十日		九个月已经结束
九月三十日
（单位：百万）
2024202320242023
预付费用$82 $44 $1,088 $396 
发展里程碑— 22 95 100 
收购了IPR&D和里程碑$82 $66 $1,183 $496 
Celsius Therapeutics, Inc.
2024年6月，艾伯维公司收购了Celsius Therapeutics， Inc.（Celsius Therapeutics），包括其主要管线资产CEL383。Celsius Therapeutics是一家致力于发现和开发炎症性肠病的精准医学的临床生物技术公司。该交易被视为资产收购，因为CEL383几乎代表所有获得的总资产的公允价值。2,000万美元的首付款在2024年第二季度的收益缩表中记录为取得的IPR＆D和里程碑费用。250百万美元的前期支付在2024年第二季度的联合简明财务报表中记录为获得的IPR&D和里程碑支出。
艾伯维公司与其他一些不重要的合作、许可协议或其他资产收购达成协议，在其中相关的前期付款计入收购的知识产权研发费用和里程碑费用中。
2024年第三季度报表 | abbvieimage2a21.gif
12

注5 合作
公司通过合作协议与其他实体有持续交易。以下列出了影响截至2024年和2023年9月30日的重要合作协议。
与詹森生物技术公司合作。
2011年12月，艾伯维公司的全资子公司Pharmacyclics与强生旗下的强生生物技术及其关联公司（Janssen）达成了全球合作和许可协议，共同开发和商业化Imbruvica，这是一种新型、口服、选择性共价Bruton酪氨酸激酶抑制剂及其与Imbruvica结构相关的某些化合物，用于肿瘤和其他疾病的治疗，但不包括所有的免疫和炎症介导疾病或病况以及所有的精神或心理疾病或病况，适用于美国和美国以外的地区。
该合作给予詹森在美国境外与AbbVie共同独家营销Imbruvica的许可，在美国与AbbVie共同独家使用。双方都将负责开发、制造和推广合作项目产生的任何产品。合作没有设定时间或特定到期日期，并提供最高100万美元的潜在未来开发、监管和批准里程碑付款给AbbVie。合作还包括一项相关合作活动的成本分享安排。除了某些情况外，詹森负责合作开发费用的约95％，而AbbVie则负责约5％的合作开发费用。200 该合作还包括一项相关合作活动的成本分享安排。除特定情况外，詹森负责大约95％的合作开发成本，而AbbVie负责剩余的约5％的合作开发成本。根据协议，除非在某些情况下，否则AbbVie将获得高达100万美元的开发、监管和批准里程碑付款。 60制造业-半导体公司艾伯维有独家合作协议，该合作还包括一项相关合作活动的成本分享安排。除特定情况外，詹森负责大约95％的合作开发成本，而艾伯维公司负责剩余的约5％的合作开发成本。 40合作开发费用的百分比。
在美国，两个公司都有共同的独占权利来商业化这些产品；但是，艾伯维公司是最终客户产品销售的主要方。艾伯维公司和杨森公司分享产品商业化的税前利润和亏损。Imbruvica的销售收入计入艾伯维公司的净收入。杨森公司的利润份额计入艾伯维公司销售成本。根据合作所发生的其他费用将根据各自的费用行项目报告，减去杨森公司的份额。
在美国以外地区，詹森公司负责并拥有 Imbruvica 的独家商业化权利。艾伯维公司和詹森公司均平分产品商业化前税前利润和损失。艾伯维公司的利润份额包含在其净收入中。在合作关系下产生的其他费用在各自的费用科目中报告，减去詹森公司的份额。
下表显示了詹森和艾伯维之间的利润和成本分摊关系：
三个月结束了
九月三十日		九个月已经结束
九月三十日
（单位：百万）2024202320242023
美国-詹森的利润份额（包含在产品销售成本中）$282 $316 $849 $925 
国际-艾伯维的利润份额（包含在净收入中）210 230 676 711 
全球——艾伯维在其他费用中所占的份额（包含在相应的细列项目中）38 59 120 171 
艾伯维公司从詹森处应收账款（扣除应收账款，净额）于2023年12月31日为 $ 万美元。233 ，于2024年9月30日约为$236 艾伯维公司欠詹森的应付款项（包括应付账款和预提费用）为 $ 万美元。282 ，于2024年9月30日约为$307 风险管理活动价格的非流动负债部分包括2023年12月31日净负债$百万美元，部分抵消了净资产百万美元的负债。
与罗氏旗下公司Genentech合作。
AbbVie and Genentech, Inc. (Genentech), a member of the Roche Group, are parties to a collaboration and license agreement executed in 2007 to jointly research, develop and commercialize human therapeutic products containing BCL-2 inhibitors and certain other compound inhibitors which includes Venclexta, a BCL-2 inhibitor used to treat certain hematological malignancies. AbbVie shares equally with Genentech all pre-tax profits and losses from the development and commercialization of Venclexta in the United States. AbbVie pays royalties on Venclexta net revenues outside the United States.
AbbVie manufactures and distributes Venclexta globally and is the principal in the end-customer product sales. Sales of Venclexta are included in AbbVie’s net revenues. Genentech’s share of United States profits is included in AbbVie’s cost of products sold. AbbVie records sales and marketing costs associated with the United States collaboration as part of SG&A expenses and global development costs as part of research and development (R&D) expenses, net of Genentech’s share. Royalties paid for Venclexta revenues outside the United States are also included in AbbVie’s cost of products sold.
2024 Form 10-Q | abbvieimage2a21.gif
13

The following table shows the profit and cost sharing relationship between Genentech and AbbVie:
Three months ended
September 30,		Nine months ended
September 30,
(in millions)2024202320242023
Genentech's share of profits, including royalties (included in cost of products sold)$263 $225 $733 $641 
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A)10 13 25 32 
AbbVie's share of development costs (included in R&D)21 24 63 82 
    
Note 6 Goodwill and Intangible Assets
Goodwill
以下表格总结了商誉带来的变化。
（以百万计）
2023年12月31日的余额$32,293 
增加(a)
2,951 
外币翻译调整51 
2024年9月30日余额$35,295 
(a) 与对immunogen和Cerevel Therapeutics的收购相关的商誉增加（见第4条款）。
公司会在第三季度或者存在减值因子时，进行其年度商誉减值评估。截至2024年9月30日， no已累计商誉减值损失。
无形资产净值
以下表格总结了无形资产:
2024年9月30日2023年12月31日
（以百万计）毛利
账面价值
ROCE 趋势可以告诉我们什么？比起 Enphase Energy，有更好的资本回报率选择。在过去的五年中，该公司增加了 1,306% 的资本，而该资本的回报率保持稳定在 9.9%。这样差的回报率现在并不令人信服，而且随着资本的增加，很明显企业并没有将资金投入到高回报的投资中。		累计
摊销		营业收入
携带
ROCE 趋势可以告诉我们什么？比起 Enphase Energy，有更好的资本回报率选择。在过去的五年中，该公司增加了 1,306% 的资本，而该资本的回报率保持稳定在 9.9%。这样差的回报率现在并不令人信服，而且随着资本的增加，很明显企业并没有将资金投入到高回报的投资中。		毛利
携带
ROCE 趋势可以告诉我们什么？比起 Enphase Energy，有更好的资本回报率选择。在过去的五年中，该公司增加了 1,306% 的资本，而该资本的回报率保持稳定在 9.9%。这样差的回报率现在并不令人信服，而且随着资本的增加，很明显企业并没有将资金投入到高回报的投资中。		累计
摊销		营业收入
carrying
ROCE 趋势可以告诉我们什么？比起 Enphase Energy，有更好的资本回报率选择。在过去的五年中，该公司增加了 1,306% 的资本，而该资本的回报率保持稳定在 9.9%。这样差的回报率现在并不令人信服，而且随着资本的增加，很明显企业并没有将资金投入到高回报的投资中。
有限寿命的无形资产
已开发产品的权益$81,721 $(26,723)$54,998 $75,142 $(22,455)$52,687 
许可协议8,316 (6,363)1,953 8,191 (5,571)2,620 
明确期限无形资产总额90,037 (33,086)56,951 83,333 (28,026)55,307 
无限生命不动产资产9,695 — 9,695 303 — 303 
总无形资产，净值$99,732 $(33,086)$66,646 $83,636 $(28,026)$55,610 
明确有限寿命的无形资产
2024年明确有限生命周期无形资产的增加主要是由于对immunogen的收购。这些无形资产将按预期经济利益模式进行摊销。有关这些收购的更多信息，请参阅附注4。
分期摊销费用为$1.9 三个月内为 XX 十亿美元，而且在简明合并损益表中成本销售包含了摊销费用。5.7 截至2024年9月30日的前九个月销售额达到亿美元2.0 三个月的销售额为亿美元，截至2023年9月30日的九个月销售额为6.1 摊销费用已包含在简明合并利润表的销售产品成本中。
2023年8月，作为2022年通胀减少法案（IRA）的一部分，公司的肿瘤学产品Imbruvica在美国销售，并被美国联邦医疗保险（CMS）选中进行谈判。这一选择导致该产品未来现金流量估值显著下降，代表了一个需要公司评估其确定的无形资产减值的触发事件。公司利用贴现现金流分析判断公允价值为$1.9 十亿，低于$4.0 十亿的账面价值，从而导致2023年8月29日在本产品的毛额和净额账面价值部分减记。根据修订后的现金流量，公司在压缩的综合财务报表中记录了$2.1 十亿的税前减值费用，列入已售出产品成本
2024年第三季度报表 | abbvieimage2a21.gif
14

2023年第三季度收益的核算。公允价值测量基于三级输入，包括预估净收入、产品成本、研发成本、销售和市场营销成本以及折现率。
无限期的无形资产
无限期无形资产代表尚未获得监管批准的产品相关的收购知识产权研发。公司每年在第三季度进行无限期无形资产的减值评估，或者如果存在减值指标，则可以提前进行。 2024年无限期无形资产的增加主要是由于对immunogen和Cerevel Therapeutics的收购。 有关收购的其他信息，请参见附注4。
2023年第一季度，公司决定修改AGN-151607的研发计划，这是一种新型实验性神经毒素，用于预防心脏手术患者的术后心房颤动。这个决定导致了预计的监管批准时间延迟，并且该产品预计未来现金流量的大幅减少，构成了一个触发事件，需要公司评估该无限期无形资产是否需要减值。公司利用折现现金流量分析来估算公允价值，其估算结果低于无形资产的账面价值。根据修订后的现金流量，公司记录了1百万美元的税前减值费用，并计入2023年第一季度的合并利润表中的研发费用。630百万美元的 研发费用 在2023年第一季度的简明合并收益表中。
注7 重组计划
艾伯维公司不断评估其运营，寻找优化其制造业-半导体和研发业务、商业基础设施以及管理成本的机会，并应对其业务环境的变化。因此，艾伯维公司管理层定期批准个别重组计划，以实现这些目标。截至2024年和2023年9月30日，并没有个别重大的重组计划。重组费用为$30 三个月的收入为xx万美元。94 截至2024年9月30日的九个月，利润为XX百万美元10 百万美元，截至2023年9月30日为$55 百万美元。这些费用根据受影响的员工或相关业务的分类记录在利润简明合并报表的销售产品成本、研发费用和销售、一般和行政费用中。
以下表格总结了截至2024年9月30日的重组储备中的现金活动：
（以百万计）
截至2023年12月31日的应计余额$196 
重组费用84 
支付和其他调整(119)
截至2024年9月30日的应计余额$161 
阿勒根整合计划
在完成对Allergan的收购后，AbbVie实施了一项整合计划，旨在降低成本，整合和优化合并后的组织，并产生了总累计费用 $2.5 截至 2023 年 12 月 31 日，将达到。这些成本包括遣散费和员工福利成本（现金遣散费、非现金遣散费，包括加速股权奖励、薪酬支出、留存和其他解雇福利）以及其他整合费用镜头。截至2023年12月31日，Allergan整合计划已基本完成，截至2024年9月30日的剩余应计金额并不大。
下表汇总了与Allergan收购整合计划相关的上一年度费用：
（单位：百万）三个月已结束
2023 年 9 月 30 日		九个月已结束
2023 年 9 月 30 日
销售产品的成本$20 $66 
研究和开发1 2 
销售、一般和管理39 134 
费用总额$60 $202 

2024 Form 10-Q | abbvieimage2a21.gif
15

注意8号 金融工具和公允价值计量
风险管理政策
See Note 11 to the company’s Annual Report on Form 10-K for the year ended December 31, 2023 for a summary of AbbVie’s risk management policy and use of derivative instruments.
Financial Instruments
Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $2.6 billion at September 30, 2024 and $1.8 billion at December 31, 2023, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than 18 months. Accumulated gains and losses as of September 30, 2024 are reclassified from accumulated other comprehensive income (loss) (AOCI) and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement.
In 2019, the company entered into treasury rate lock agreements with notional amounts totaling $10.0 billion to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the issuance of long-term debt in connection with the acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and recorded at fair value. The agreements were net settled upon issuance of the senior notes in 2019 and the resulting net gain was recognized in AOCI. This gain is reclassified to interest expense, net over the term of the related debt.
In June 2023, the company entered into a cross-currency swap contract that matured in November 2023 with a notional amount totaling €433 million to hedge the company’s exposure to changes in future cash flows of foreign currency denominated debt related to changes in foreign exchange rates. The cross-currency swap contract was designated as a cash flow hedge and effectively converted the interest and principal payments of the related foreign currency denominated debt to U.S. dollars. The unrealized gains and losses on the contract were included in AOCI and reclassified to net foreign exchange loss over the term of the related debt.
The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the condensed consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $7.7 billion at September 30, 2024 and $7.9 billion at December 31, 2023.
The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had an aggregate principal amount of senior Euro notes designated as net investment hedges of €3.2 billion at September 30, 2024 and €5.4 billion at December 31, 2023. In addition, the company had foreign currency forward exchange contracts designated as net investment hedges with notional amounts totaling €6.2 billion, SEK1.9 billion, CAD750 million and CHF70 million at September 30, 2024 and €4.9 billion, SEK1.4 billion, CAD750 million and CHF50 million at December 31, 2023. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument.
该公司与利率掉期合约方共同签订的公允价值套期保值包括6月30日总标名为$10亿的利率掉期合约和12月31日总标名为$20亿的利率掉期合约。套期保值合约的效应是将负债的一部分从固定利率变成浮动利率。AbbVie以公允价值来记录合约，并调整固定利率负债的账面金额。3.5 十亿，2013年12月31日为$5.0 套期保值合约的效应是将一固定利率利息义务变为负债的浮动利率部分。AbbVie以公允价值来记录合约，并调整固定利率负债的账面金额。截至2023年12月31日，共有标名为$20亿的利率掉期合约。
No 金额不计入现金流量套期保值或公允价值套期保值的有效性评估。
2024年第三季度报表 | abbvieimage2a21.gif
16

以下表格总结了艾伯维公司衍生工具的金额和位置，列在简明合并资产负债表上：
公允价值 -
资产位置中的衍生品		公允价值 -
以负债持仓的衍生工具
（以百万计）资产负债表说明September 30,
2024		截至12月31日公允价值
2023		资产负债表说明September 30,
2024		截至12月31日公允价值
2023
外汇远期汇率交易合同
指定为现金流量套期保值预付费用和其他$8 $12 应付账款及应计费用$45 $32 
指定为净投资风险对冲预付费用和其他12 13 应付账款及应计费用32 66 
指定为净投资套期保值其他— — 其他长期负债108 69 
未指定为对冲工具预付费用和其他24 41 应付账款及应计费用17 36 
利率掉期合同
指定为公允价值对冲工具其他— — 其他长期负债244 293 
衍生品总额$44 $66 $446 $496 
虽然公司与其交易对手存在一定的净額安排，但公司未在公司简明合并资产负债表内抵销衍生资产和负债。
下表显示了其他综合收益中承认的衍生工具收益（损失）的税前金额：
截至三个月结束
September 30,		九个月结束
September 30,
（单位百万）2024202320242023
外汇远期汇率交易合同
指定为现金流量套期保值$(45)$76 $30 $81 
指定为净投资风险对冲(238)241 (16)153 
指定为现金流量对冲的跨货币掉期合约— (14)— (5)
如果市场汇率在合同到期前保持不变，该公司预计在未经税前收益方面将$货币重新分类为产品销售成本，并在下一个12个月中将$货币的未经税前收益重新分类为利息开支，净额，以用于金库汇率锁定协议现金流风险对冲。6如果市场汇率在合同到期前保持不变，该公司预计将$货币的未经税前收益重新分类为外汇现金流量套期保值的产品销售成本，并在下一个12个月中将$货币的未经税前收益重新分类为利息支出，净额，以用于金库汇率锁定协议现金流风险对冲。21 假设市场利率在合同到期前保持不变，公司预计在未来的12个月内，将$货币的未经税前收益重新分类为金库利率锁定协议现金流量套期保值的利息支出，净额。
关于艾伯维公司的非衍生工具，以外币计价的债务被确认为净投资套期保值，公司在其他全面收益（损失）中认可了税前损失$151 百万美元，截至2024年9月30日三个月的税前损失$百万美元和九个月的税前损失$百万美元56 并且三个月的税前盈利$百万美元和九个月的税前盈利$百万美元173 三个月的税前盈利$百万美元47 百万美元。
2024年第三季度报表 | abbvieimage2a21.gif
17

以下表格总结了金融工具净收益（损失）的税前金额和地点，包括从其他综合收益重新分类出的净收益（损失）转入净收益的金额。有关从其他综合收益重新分类出的净收益（损失）金额，请参见注释10。
截至三个月结束
September 30,		九个月结束
September 30,
（以百万计）损益表说明2024202320242023
外汇远期汇率交易合同
指定为现金流量套期保值销售产品成本$19 $11 $41 $67 
指定为净投资风险对冲利息费用，净额32 28 90 85 
未指定为对冲工具净外汇损益(30)(41)(14)(7)
指定为现金流量对冲的国库利率锁定协议利息费用，净额6 6 18 18 
指定为现金流量对冲的跨货币掉期合约净外汇损益— (14)— (6)
利率掉期合同
指定为公允价值对冲工具利息费用，净额60 (58)49 (44)
债务作为公允价值对冲的被对冲项目利息费用，净额(60)58 (49)44 
公允价值衡量
公允价值层级包括以下三个级别:
•一级 - 根据公司能够获取的相同资产在活跃市场上的未调整报价进行估值;
•二级-根据活跃市场中类似工具的报价、在不活跃市场中相同或类似工具的报价和模型估值，其中所有重要输入都在市场上是可观察的；以及
•三级 - 估值采用市场中不可观察的重要输入，并且包括公司管理层对市场参与者在定价资产或负债时所使用假设的判断。
下表总结了2024年9月30日资产负债表上按照重要性测量的一些资产和负债的基础。
公允价值计价基础
（以百万计）总计相同资产在活跃市场上的报价价格
(一级)		其他重要可观察到的数据
输入
(2级)		重要的不可观察输入
（三级）
资产
现金及现金等价物$7,257 $6,080 $1,177 $— 
货币市场基金和定期存款10 — 10 — 
债务证券32 — 32 — 
股票投资100 71 29 — 
外币合同44 — 44 — 
资产总额$7,443 $6,151 $1,292 $— 
负债
利率掉期合同$244 $— $244 $— 
外币合同202 — 202 — 
融资负债253 — — 253 
或有事项考虑21,926 — — 21,926 
负债合计$22,625 $— $446 $22,179 
2024年第三季度报表 | abbvieimage2a21.gif
18

下表总结了截至2023年12月31日，在周期性合并资产负债表上计量的某些资产和负债的计价基础:
公允价值计价基础
（以百万计）总计相同资产在活跃市场上的报价价格
(一级)		其他重要可观测因素
inputs
(2级)		重要的不可观察输入
（三级）
资产
现金及现金等价物$12,814 $6,223 $6,591 $— 
货币市场基金和定期存款10 — 10 — 
债务证券26 — 26 — 
股权证券111 86 25 — 
外币合同66 — 66 — 
资产总额$13,027 $6,309 $6,718 $— 
负债
利率掉期合同$293 $— $293 $— 
外币合约203 — 203 — 
或有事项考虑19,890 — — 19,890 
负债合计$20,386 $— $496 $19,890 
所有基金类型和定期存款的价值是使用相关可观测市场输入进行计算，包括相似资产的报价和利率曲线。股票投资主要是按每单位发布的市场价格乘以持有单位数量的方式确定公允价值，不考虑交易成本。公司所参与的衍生品是使用可观测市场输入进行价值计算的，包括发布的利率曲线和外币远期和即期价格。
融资责任与Cerevel Therapeutics在收购前签订的融资协议有关，并由AbbVie承担。融资协议代表按照融资安排予以核算的金融工具，公司选择按照ASC 825规定的公平价值选择来核算融资责任。 金融工具融资责任的公允价值衡量是基于重要的不可观测输入确定的。潜在支付是通过应用概率加权的预期支付模型进行估计, 对于监管里程碑支付, 以及通过蒙特卡洛模拟模型进行估计进行销售里程碑和版税支付, 然后进行折现到现值。融资责任的公允价值的变动，可能由一个或多个因素的变化导致，包括贴现率、估计概率、达成里程碑的时间以及未来销售金额的估计。 公允价值的变动， 通过确认为净损益中的其他费用（收入），在简明综合损益表和与特定工具信用风险相关的公允价值变动，被确认在其他综合损失中。2024年9月30日结束的三个月内，公允价值的变动记录在净利润中的其他费用（收入），净和其他综合损失中并不显著。
有关待定条件负债的公允价值测量是基于重要的不可观测输入确定的，包括贴现率、预估概率和实现指定发展、监管和商业里程碑的时间，以及收购产品未来销售额的估计金额。潜在的待定条件支付金额是通过应用概率加权的预期支付模型计算待定里程碑支付额，以及通过蒙特卡洛模拟模型计算待定版税支付额，然后将其折现至现值。待定条件负债的公允价值变动可能源自一个或多个输入的变动，包括贴现率、实现里程碑的概率、实现里程碑所需时间以及未来销售额的估计。在确定这些输入的恰当性时需要做出重大判断。上述输入的变动可能对公司在任何给定期间的财务状况和运营结果产生重大影响。
2024年第三季度报表 | abbvieimage2a21.gif
19

公司可能需要支付的未决考虑负债的公允价值是通过以下重要的无法观测的输入因素计算得出的:
2024年9月30日2023年12月31日
区间
加权平均值(a)
区间
加权平均值(a)
折现率
3.9% - 5.1%
4.1%
4.3% - 5.9%
4.5%
按适应症支付版税的概率(b)
100% - 100%
100%
89% - 100%
99%
支付年份的预测
2024 - 2034
2028
2024 - 2034
2027
(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.
(b) Excluding approved indications, the estimated probability of payment was 89% at December 31, 2023.
There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs:
Nine months ended
September 30,
(in millions)20242023
Beginning balance$19,890 $16,384 
Change in fair value recognized in net earnings3,492 3,432 
Payments(1,456)(1,142)
Ending balance$21,926 $18,674 
公允价值变动，确认在净收益中记录在简明合并资产负债表的其他费用（收入）。直至初始收购日期公允价值的待定补偿支付被分类为融资活动的现金流出，超过初始收购日期公允价值的支付则被分类为经营活动的现金流出在简明合并现金流量表中。
某些金融工具按历史成本或某种基础计量，而非按公允价值计量。 2024年9月30日的某些金融工具的账面价值、近似公允价值和用于衡量近似公允价值的基础如下表所示：
Basis of fair value measurement
(in millions)Book valueApproximate fair valueQuoted prices in active markets for identical assets
(Level 1)		Significant other 
observable inputs
(Level 2)		Significant unobservable inputs
(Level 3)
Liabilities
Current portion of long-term debt and finance lease obligations, excluding fair value hedges$12,558 $12,486 $12,341 $145 $— 
Long-term debt and finance lease obligations, excluding fair value hedges58,500 57,177 56,747 430 — 
Total liabilities$71,058 $69,663 $69,088 $575 $— 
2024 Form 10-Q | abbvieimage2a21.gif
20

截至2023年12月31日，账面价值、近似公允价值和用于衡量某些金融工具近似公允价值的基数如下表所示：
公允价值计量的基础
（单位：百万）账面价值近似公允价值相同资产在活跃市场上的报价
（第 1 级）		其他重要的
可观察的输入
（第 2 级）		大量不可观察的输入
（第 3 级）
负债
长期债务和融资租赁债务的流动部分，不包括公允价值套期保值$7,191 $7,069 $6,862 $207 $— 
长期债务和融资租赁债务，不包括公允价值套期保值52,460 49,541 48,983 558 — 
负债总额$59,651 $56,610 $55,845 $765 $— 
AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $153 million as of September 30, 2024 and $159 million as of December 31, 2023. No significant cumulative upward or downward adjustments have been recorded for these investments as of September 30, 2024.
Concentrations of Risk
Of total net accounts receivable, three U.S. wholesalers accounted for 78% as of September 30, 2024 and 81% as of December 31, 2023, and substantially all of AbbVie’s pharmaceutical product net revenues in the United States were to these three wholesalers.
Debt and Credit Facilities
Financing Related to ImmunoGen and Cerevel Therapeutics Acquisitions
In connection with the acquisitions of ImmunoGen and Cerevel Therapeutics, in February, 2024, the company issued $15.0 billion aggregate principal amount of unsecured senior notes. The notes are unsecured, unsubordinated obligations of AbbVie and will rank equally in right of payment with all of AbbVie’s existing and future unsecured, unsubordinated indebtedness, liabilities and other obligations. AbbVie may redeem the fixed-rate senior notes prior to maturity at a redemption price equal to the greater of the principal amount or the sum of present values of the remaining scheduled payments of principal and interest on the fixed-rate senior notes to be redeemed plus a make-whole premium. AbbVie may also redeem the fixed-rate senior notes at par between one and six months prior to maturity. In connection with the offering, debt issuance costs incurred totaled $99 million and debt discounts totaled $37 million, which are being amortized over the respective terms of the notes to interest expense, net in the condensed consolidated statements of earnings.
AbbVie used the net proceeds received from the issuance of the notes to finance the acquisition of ImmunoGen, repay its term-loan, repay commercial paper borrowings, pay fees and expenses in respect of the foregoing, finance general corporate purposes and, together with cash on hand, fund AbbVie’s acquisition of Cerevel Therapeutics. See Note 4 for additional information.
2024 Form 10-Q | abbvieimage2a21.gif
21

The following table summarizes issued debt in connection with the acquisitions of ImmunoGen and Cerevel Therapeutics:
(in millions)
Senior Notes
4.80% Senior Notes due 2027$2,250 
4.80% Senior Notes due 20292,500 
4.95% Senior Notes due 20312,000 
5.05% Senior Notes due 20343,000 
5.35% Senior Notes due 2044750 
5.40% Senior Notes due 20543,000 
5.50% Senior Notes due 20641,500 
Total debt issued$15,000 
In December 2023, AbbVie entered into a $9.0 billion 364-day bridge credit agreement and $5.0 billion 364-day term loan credit agreement. In February 2024, AbbVie borrowed and repaid $5.0 billion under the term loan credit agreement. Interest charged on this borrowing was based on Secured Overnight Financing Rate Reference Rate (SOFR) +0.975% with an effective interest rate of 6.29%. Subsequent to the $15.0 billion issuance of senior notes, AbbVie terminated both the bridge and term loan credit agreements in the first quarter of 2024. In February 2024, concurrent with the ImmunoGen acquisition, the company assumed and repaid an ImmunoGen senior secured term loan at a fair value of $99 million.
In connection with the acquisition of Cerevel Therapeutics, the company assumed $345 million aggregate principal of 2.5% convertible senior notes due 2027. Upon acquisition, the convertible senior notes became callable and note holders could redeem the convertible senior notes for cash at a premium. As of the acquisition date, the convertible senior notes were recognized as current portion of long-term debt on the condensed consolidated balance sheets at an aggregate fair value of $400 million. Following the acquisition date, the company repaid the convertible senior notes and there were no amounts outstanding as of September 30, 2024.
公司还承担了艾伯维公司收购之前Cerevel Therapeutics签订的资金协议。根据这些协议，Cerevel Therapeutics获得了资金来支持tavapadon的开发，并同意根据美国食品和药物管理局（FDA）批准tavapadon后偿还监管里程碑、销售里程碑和版税。此外，在收购时，公司可以选择提前偿还付款义务，支付金额等于向Cerevel Therapeutics提供的资金金额再加上一个变量的溢价。在任何情况下，资金协议下的总偿还款项不会超过$531百万美元。这些融资协议按照融资安排进行了核算，与相关融资负债的公允价值为$246百万，截至收购日期。与资金协议同时，艾伯维公司还承担了艾伯维公司在收购前与Cerevel Therapeutics签订的安全协议，根据这些协议，Cerevel Therapeutics向资金投资者抵押了在美国开发和商业化tavapadon过程中重要的资产。
其他长期债务
In May 2024, the company repaid a €1.5 billion aggregate principal amount of 1.38% senior euro notes at maturity.
In June 2024, the company repaid a €700 million aggregate principal amount of 1.25% senior euro notes and $1.0 billion aggregate principal amount of 3.85% senior notes at maturity.
Subsequent to September 30, 2024, the company refinanced its $2.0 billion floating rate three-year term loan. As part of the refinancing, the company repaid the existing $2.0 billion term loan due May 2025 and borrowed $2.0 billion under a new term loan due April 2027.
In January 2023, the company repaid a $1.0 billion floating rate three-year term loan that was scheduled to mature in May 2023. In March 2023, the company repaid a $350 million aggregate principal amount of 2.80% senior notes at maturity.
In May 2023, the company repaid $1.0 billion aggregate principal amount of 2.85% senior notes at maturity.
Short-Term Borrowings
During the nine months ended September 30, 2024, the company issued and redeemed $1.7 billion of commercial paper. There were no commercial paper borrowings outstanding as of September 30, 2024 and December 31, 2023. The weighted average interest rate on commercial paper borrowings was 5.54% for the nine months ended September 30, 2024.
2024 Form 10-Q | abbvieimage2a21.gif
22

2023年3月，艾伯维公司进入一份修改后和重新陈述的循环信贷授信协议。该修正方案将未担保循环信贷授信额度从10亿美元增加至15亿美元，并将该协议到期日从2023年8月延长至2028年3月。这份修改后的授信协议让公司可以以可变利率的方式以无担保形式借款并包含各种契约。截至2024年6月30日，公司符合所有契约义务，授信额度下的承诺费微不足道。截至2024年6月30日和2023年12月31日，公司信贷授信额度下的欠款金额均无显著变化。 五年 修正方案增加了无抵押循环授信承诺金额从$10亿至$15亿，并将授信协议的到期日从2023年8月延长至2028年3月。修订后的方案使该公司能够以可变利率和包含各种契约的方式在无抵押基础上借款。截至2024年6月30日，公司符合所有契约条款，授信额度下的承诺费微不足道。2024年6月30日和2023年12月31日，该公司信贷额度下的欠款金额均未有显著变化。4.0亿美元增加至 $5.0 借款额扩大至数十亿美元，并将设施的到期日从2023年8月延长至2028年3月。这一修订后的设施使公司能够按照变量利率无抵押的方式借入资金，并包含各种契约。截至2024年9月30日，公司已经符合所有契约，并且信贷设施下的承诺费用微乎其微。 No 截至2024年9月30日和2023年12月31日，公司信贷额度下的借款金额已全部结清。

Note 9 Post-Employment Benefits
The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans:
Defined
benefit plans		Other post-
employment plans
Three months ended
September 30,		Nine months ended
September 30,		Three months ended
September 30,		Nine months ended
September 30,
(in millions)20242023202420232024202320242023
Service cost$71 $68 $214 $203 $11 $9 $32 $27 
Interest cost113 108 339 324 10 9 31 28 
Expected return on plan assets(196)(181)(589)(543)— — — — 
Amortization of prior service cost (credit)— — — 1 (9)(9)(27)(27)
Amortization of actuarial loss13 4 39 12 4 3 13 9 
Net periodic benefit cost (credit)$1 $(1)$3 $(3)$16 $12 $49 $37 
The components of net periodic benefit cost other than service cost are included in other expense (income), net in the condensed consolidated statements of earnings.
2024 Form 10-Q | abbvieimage2a21.gif
23

Note 10 Equity
Stock-Based Compensation
Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the AbbVie Amended and Restated 2013 Incentive Stock Program and is summarized as follows:
Three months ended
September 30,		Nine months ended
September 30,
(in millions)2024202320242023
Cost of products sold$12 $9 $44 $38 
Research and development67 53 274 227 
Selling, general and administrative102 68 429 357 
Pre-tax compensation expense181 130 747 622 
Tax benefit(33)(26)(127)(111)
After-tax compensation expense$148 $104 $620 $511 
In addition to stock-based compensation expense included in the table above and in connection with the acquisitions of ImmunoGen and Cerevel Therapeutics, AbbVie incurred cash-settled, post-closing expense for ImmunoGen and Cerevel Therapeutics employee incentive awards, which is summarized in the table below:
(in millions)
Three months ended September 30, 2024
Nine months ended September 30, 2024
Cost of products sold$5 $36 
Research and development
58184
Selling, general and administrative98290
Total post-closing cash settled expense
$161 $510 
股票期权
2024年9月30日结束的九个月期间，主要与公司的年度授予相关，艾伯维公司授予 0.6百万股期权，期权的加权平均授予日公平价值为$31.53截至2024年9月30日，8 预计将在接下来的大约下一个期间内予以核算为费用。 发生.
RSU和绩效股
During the nine months ended September 30, 2024, primarily in connection with the company's annual grant, AbbVie granted 5.5 million RSUs and performance shares with a weighted-average grant-date fair value of $176.43. During the nine months ended September 30, 2024 and in connection with the ImmunoGen and Cerevel Therapeutics acquisitions, AbbVie issued 0.6 million RSUs to holders of ImmunoGen and Cerevel Therapeutics equity awards based on a conversion factor described in each of the transaction agreements. See Note 4 for additional information regarding the ImmunoGen and Cerevel Therapeutics acquisitions. As of September 30, 2024, $799 million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years.
Cash Dividends
The following table summarizes quarterly cash dividends declared during 2024 and 2023:
20242023
Date DeclaredPayment Date
Dividend Per Share
Date Declared
Payment Date
Dividend Per Share
10/30/2402/14/25$1.64 10/26/2302/15/24$1.55 
09/06/2411/15/24$1.55 09/08/2311/15/23$1.48 
06/21/2408/15/24$1.55 06/22/2308/15/23$1.48 
02/15/2405/15/24$1.55 02/16/2305/15/23$1.48 
2024 Form 10-Q | abbvieimage2a21.gif
24

股票回购计划
公司的股票回购授权允许在管理层自行决定时，随时进行公开市场或私人交易的艾伯维公司股票购买。该计划没有时间限制，可以随时停止。在此计划下回购的股票记录在收购成本中，包括相关费用，并可用于一般企业用途。
On February 16, 2023, AbbVie’s board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization. AbbVie repurchased 5 million shares for $959 million during the nine months ended September 30, 2024 and 10 million shares for $1.6 billion during the nine months ended September 30, 2023. AbbVie's remaining stock repurchase authorization was approximately $3.9 billion as of September 30, 2024.
Accumulated Other Comprehensive Loss
The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2024:
(in millions)Foreign currency
translation adjustments
Net investment
hedging activities
Pension 
and post-employment
benefits
Cash flow hedging
activities		Total
Balance as of December 31, 2023$(1,106)$65 $(1,488)$224 $(2,305)
Other comprehensive income (loss) before reclassifications21 31 (4)20 68 
Net losses (gains) reclassified from accumulated other comprehensive loss— (70)19 (46)(97)
Net current-period other comprehensive income (loss)21 (39)15 (26)(29)
Balance as of September 30, 2024$(1,085)$26 $(1,473)$198 $(2,334)
以下表格总结了2023年9月30日结束的九个月内各个组成部分的累计其他全面损失净额变化，扣除税后。
（以百万计）外汇
汇兑调整
净投资
避险活动
养老金
和退休后
燃料、营业费用和供应品		现金流避险
活动		总计
2022年12月31日余额$(1,513)$464 $(1,458)$308 $(2,199)
其他综合收益（损失）在再分类之前(279)156 43 61 (19)
从累计其他综合损失中重新分类的净收益— (67)(5)(63)(135)
净本期其他综合收益（损失）(279)89 38 (2)(154)
截至2023年9月30日的余额$(1,792)$553 $(1,420)$306 $(2,353)
2023年9月30日止九个月的其他综合损失包括外币翻译调整，总计损失$279 其中净投资对冲活动获得 $ 利润，主要由于欧元贬值对公司以欧元计价的资产的影响的抵消。89百万美元。
2024年第三季度报表 | abbvieimage2a21.gif
25

下表呈示了艾伯维公司其他综合收益损益各组成部分中重分类的重要金额对压缩合并利润表的影响：
截至三个月结束
September 30,		九个月结束
September 30,
（单位：百万美元）（括号内表示获得收益）2024202320242023
净投资套期保值活动
衍生品收益被排除在有效性测试之外(a)
$(32)$(28)$(90)$(85)
所得税费7 6 20 18 
重分类总额，净额（税后）$(25)$(22)$(70)$(67)
养老金和离退休福利
摊销精算损益（盈利）和其他(b)
$8 $(2)$25 $(5)
税收优惠(2)— (6)— 
总重新分类，净税后$6 $(2)$19 $(5)
现金流量套期保值活动
外币远期汇兑合约收益(c)
$(19)$(11)$(41)$(67)
购买国库利率锁定协议的收益(a)
(6)(6)(18)(18)
跨货币掉期合同的收益(d)
— 14 — 6 
所得税费
5 2 13 16 
重新分类总额，税后净额$(20)$(1)$(46)$(63)
(a) Amounts are included in interest expense, net (see Note 8).
(b) Amounts are included in the computation of net periodic benefit cost (see Note 9).
(c) Amounts are included in cost of products sold (see Note 8).
(d) Amounts are included in net foreign exchange loss (gain) (see Note 8).
Note 11 Income Taxes
The effective tax rate was 25% for the three months and 28% for the nine months ended September 30, 2024 compared to 9% for the three months and 20% for the nine months ended September 30, 2023. The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, changes in fair value of contingent consideration and business development activities, including ImmunoGen and Cerevel Therapeutics acquisition-related costs. The increase in the effective tax rate for the three months ended September 30, 2024 over the prior year was primarily due to changes in fair value of contingent consideration, impact of foreign operations and business development activities. The increase in the effective tax rate for the nine months ended September 30, 2024 over the prior year was primarily due to the impact of foreign operations and business development activities.
It is reasonably possible that the company’s gross unrecognized tax benefits balance may change within the next 12 months by up to $58 million in connection with statute of limitation expirations. The company has various federal, state and foreign examinations ongoing. Finalizing examinations with the relevant taxing authorities can include formal administrative and legal proceedings, and as a result, we cannot reasonably estimate the timing of resolution for certain unrecognized tax benefits.
Subsequent to September 30, 2024, the company was notified that the administrative proceeding related to its U.S. federal income tax examination for certain tax years was substantially completed. Final resolution of examination of such years may occur in the fourth quarter of 2024. The company anticipates that final resolution will result in a decrease in the gross amount of unrecognized tax benefits on the condensed consolidated balance sheets and recognition of an income tax benefit in the condensed consolidated statement of earnings, which could be material. The Company does not anticipate that such resolution will have a significant impact on its cash flows.
2024年第三季度报表 | abbvieimage2a21.gif
26

附注12 法律诉讼和意外事项
艾伯维公司受到各种索赔、法律诉讼和调查的风险，涉及产品责任、知识产权、商业、证券和其他在业务正常运作过程中出现的事项。在管理层最佳估计损失的情况下，会为可能发生的损失记录损失风险准备金，或者在无法做出最佳估计的情况下，将在可能区间内的最低损失风险金额记录下来。诉讼的记录准备金余额截至2024年9月为约$2.4亿美元，截至2023年12月为$2.0亿美元。对于下文讨论的涉及可能或可能发生损失的诉讼事项，公司无法估计除已计提金额外的可能损失或损失区间。新的法律程序的启动或现有程序状态的变化可能导致艾伯维公司已计提的估计损失发生变化。虽然无法确切预测所有诉讼和风险的结果，但管理层相信其最终处理不应对艾伯维公司的综合财务状况、经营业绩或现金流产生重大不利影响。
除了雅培与艾伯维之间规定的特定例外情况外，艾伯维将承担并控制与其业务相关的所有现有和威胁的法律事项的责任，包括与其业务有关的产品之前停产但仍有相关索赔或法律程序的负债，以及承担或保留的责任，并将为因此类承担的法律事项向雅培提供赔偿。
反垄断诉讼
针对艾伯维公司及其他公司的诉讼通常指控涉及Niaspan的2005年专利诉讼和解，这是Kos Pharmaceuticals公司（现为Abbott于2006年收购的子公司）与一个仿制药公司之间达成的，并违反了联邦和州反垄断法，州不公平和欺骗性商业做法和不当得利法。原告通常寻求经济赔偿和/或禁令救济和律师费。联邦法院中正在等待处理的诉讼包括单个原告诉讼和Niaspan直接购买者的集体诉讼。这些案件正在宾夕法尼亚州东区联邦地区法院等待协调或合并审前程序，在多重起诉 (MDL) 规则下进行，此案的MDL编号为2460案。2016年10月，加利福尼亚州橙县地区检察官办公室在橙县高等法院代表加州提起针对Niaspan专利诉讼和解的诉讼，根据加州商业和职业法的不正当竞争条款寻求禁令救济、赔偿、民事罚款和律师费。 六个 Niaspan个体购买者已经作为一个认证类别的集体诉讼而存在，以联邦多元诉讼 (MDL)规则的“Niaspan反垄断诉讼”为名，由美国宾夕法尼亚州东区联邦地区法院处理协调或合并审前程序，MDL编号为2460案。
2019年8月，AndroGel的直接购买者在宾夕法尼亚东部地区联邦地区法院对AbbVie和其他被告提起诉讼，原告指控Solvay Pharmaceuticals，Inc.(Abbott于2010年2月收购并现在已改名为AbbVie Products LLC的公司)在2006年的专利诉讼和相关协议中与通用药公司达成的和解违反了联邦反垄断法，并声称Abbott与两家通用药公司就AndroGel的2011年专利诉讼是虚假诉讼，解决此类诉讼的和解违反了联邦反垄断法。原告一般寻求金钱赔偿和/或禁令救济以及律师费。2022年11月，俄勒冈州在Multnomah县俄勒冈州巡回法院提起诉讼，针对的是与一家通用药公司的2011年专利诉讼的类似指控。 三 普通公司违反了联邦反垄断法，并声称2011年由Abbott与两家普通公司就AndroGel进行的专利诉讼是伪诉讼，这些诉讼的和解违反了联邦反垄断法。 2024年9月，艾伯维公司和原告达成一项解决此诉讼的协议。 2022年11月，俄勒冈州在俄勒冈州多诺玛县法院提起诉讼，指控类似的情况，涉及2011年与一家普通公司的专利诉讼。
政府程序
Allergan和几家其他制造商面临诉讼，普遍指控他们不当地推广和销售处方阿片类药品。大约 440 个针对Allergan的诉讼正在联邦和州法院等待裁决。大多数联邦法院的诉讼根据MDL规则在俄亥俄州北部地区的美国地方法院进行预审，案号为In re: National Prescription Opiate Litigation, MDL No. 2804.其中约 35 的诉讼在各州法院等待裁决。这些诉讼的原告包括州政府，县市，其他市政实体，美国原住民部落，信托基金和其他第三方支付方，民营医院和人身伤害索赔人，通常都要求获得赔偿和惩罚性赔偿金。其中大约 440 诉讼，其中大约 30 由州政府，县市和其他市政实体提起，其中约 10 其中一些正在根据先前宣布的和解协议被解雇。另外，大约 45 其中大约 440 其他诉讼纠纷将由爱尔康和急救医院类团体提出的集体和解协议覆盖，需要法院批准和其他不确定因素。
2023年3月，雅培制药及其子公司对美国国家税务法庭提起诉讼，雅培制药及其子公司诉内部税收局委员会。该诉讼是关于2014年与第三方支付终止拟议业务合并的收益税款抵免的。5722014年记录的与向第三方支付的涉及终止拟议业务合并的款项相关的1000万美元所得税收益。
2024年第三季度报表 | abbvieimage2a21.gif
27

股东和证券诉讼
2018年10月，在美国伊利诺伊州北区联邦地方法院，发生了一起联邦证券诉讼，霍尔威尔诉艾伯维公司等案。该案针对艾伯维公司、其首席执行官和前首席财务官，指控称2013年至2018年的财务文件中列明的Humira销售增长原因具有误导性，因为它们忽略了有争议的有关Humira患者和报销支持服务以及其他服务和据称促进Humira处方的价值物品的不当行为。2021年9月，法院批准原告的类别诉讼动议。
2022年5月和7月，特雷普尔家族信托诉冈萨雷斯等股东衍生诉讼案以及卡切尔诉冈萨雷斯等案在美国伊利诺伊州北区联邦地区法院提起，声称某些艾伯维公司董事和高管在发表或容许关于另一家公司产品安全信息可能对食品药品监督管理局批准和标注艾伯维公司Rinvoq的潜在影响方面存在违反受托责任和其他法律义务的陈述或允许。2024年10月，法院裁定驳回被告的无可裁酌的驳回动议。
产品责任和一般诉讼
2023年4月，在美国伊利诺伊北部联邦地区法院，一宗名为 Camargo v. AbbVie Inc. 的集体诉讼案件被提起，代表那些基于 Humira 的定价或因失去保险而无法支付其定价而停止使用 Humira 的患者，声称 Humira 的定价过高，违反多个州不公平和欺骗性商业行为法。原告一般寻求货币赔偿、禁令救济和律师费。
In 2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al., was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator sought damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit. In March 2023, the court granted Allergan’s motion to dismiss, dismissing plaintiff-relator’s federal law claims with prejudice and state law claims without prejudice. The plaintiff-relator is appealing the court’s motion to dismiss ruling.
Lawsuits are pending against various Allergan entities in the United States and other countries including Brazil, Canada, South Korea, and the Netherlands, in which plaintiffs generally allege that they developed, or may develop, breast implant-associated anaplastic large cell lymphoma (ALCL) or other injuries from Allergan’s Biocell® textured breast implants, which were voluntarily withdrawn from worldwide markets in 2019. Approximately 130 ALCL lawsuits and 1,000 other lawsuits are coordinated for pre-trial purposes in the United States District Court for the District of New Jersey under the MDL rules as In re: Allergan Biocell Textured Breast Implant Product Liability Litigation, MDL No. 2921. Approximately 75 ALCL lawsuits and 460 other lawsuits are pending in various state courts. Approximately 50 ALCL and 800 other lawsuits are pending in other countries. Plaintiffs generally seek monetary damages, medical monitoring, and attorneys’ fees.
Intellectual Property Litigation
AbbVie Inc. is seeking to enforce patent rights relating to venetoclax (a drug sold under the trademark Venclexta). Litigation was filed in the United States District Court for the District of Delaware in July 2020 against Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. AbbVie alleges defendants’ proposed generic venetoclax products infringe certain patents and seeks declaratory and injunctive relief. Genentech, Inc., which is in a global collaboration with AbbVie concerning the development and marketing of Venclexta, is the co-plaintiff in this suit.
AbbVie Inc. is seeking to enforce patent rights relating to upadacitinib (a drug sold under the trademark Rinvoq). Litigation was filed in the United States District Court for the District of Delaware in November 2023 against Hetero USA, Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Aurobindo Pharma USA, Inc., Aurobindo Pharma Ltd., Sandoz, Inc. Sandoz Private Limited, Sandoz GMBH, and Sun Pharmaceutical Industries, Ltd. AbbVie alleges defendants’ proposed generic upadacitinib products infringe certain patents and seeks declaratory and injunctive relief.
AbbVie Inc. is seeking to enforce patent rights related to ubrogepant (a drug sold under the trademark Ubrelvy). Litigation was filed in the United States District Court for the District of New Jersey in March 2024 against Aurobindo Pharma U.S.A., Inc., Aurobindo Pharma Limited, and Apitoria Pharma Private Limited; Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited; MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited; and Hetero USA Inc., Hetero Labs Limited Unit-III, and Hetero Labs Limited. AbbVie alleges defendants’ proposed generic ubrogepant products infringe certain patents and seeks declaratory and injunctive relief. Merck Sharp & Dohme LLC, which exclusively licenses certain patents to AbbVie, is a co-plaintiff in the litigation.
2024 Form 10-Q | abbvieimage2a21.gif
28

备注13 分段信息
AbbVie作为一个全球业务领域运营，致力于创新药物和治疗方法的研究和开发、制造、商业化和销售。这种运营结构使首席执行官作为首席运营决策者(CODM)能够在全球范围内分配资源并评估业务绩效，以实现既定的长期战略目标。与此结构一致的是，负责产品发现、制造和供应的全球研发和供应链组织。协调这些产品的营销、销售和分销的商业活动则由地理区域或治疗领域组织。所有这些活动都由全球企业行政人员支持。确定单一业务领域符合CODm定期审查的合并财务信息，以评估绩效、分配资源和规划和预测未来时期的目的。
下表详细说明了艾伯维的全球净收入：
三个月结束了
九月三十日		九个月已经结束
九月三十日
（单位：百万）2024202320242023
免疫学
Humira美国$1,765 $3,020 $5,896 $9,420 
国际462 527 1,415 1,680 
总计$2,227 $3,547 $7,311 $11,100 
Skyrizi美国$2,778 $1,875 $6,774 $4,648 
国际427 251 1,166 721 
总计$3,205 $2,126 $7,940 $5,369 
Rinvoq美国$1,170 $801 $2,912 $1,895 
国际444 309 1,225 819 
总计$1,614 $1,110 $4,137 $2,714 
肿瘤学
Imbruvica美国$618 $678 $1,823 $1,982 
协作收入210 230 676 711 
总计$828 $908 $2,499 $2,693 
Venclexta美国$340 $281 $921 $811 
国际337 309 1,007 888 
总计$677 $590 $1,928 $1,699 
Elahere(a)
美国
$139 $— $331 $— 
Epkinly协作收入$31 $14 $82 $14 
国际12 — 24 — 
总计$43 $14 $106 $14 
美学
肉毒杆菌毒素化妆品美国$414 $388 $1,253 $1,217 
国际257 232 780 747 
总计$671 $620 $2,033 $1,964 
Juvederm 系列美国$105 $116 $349 $363 
国际153 205 549 681 
总计$258 $321 $898 $1,044 
其他美学美国$272 $255 $828 $785 
国际38 43 119 130 
总计$310 $298 $947 $915 
神经科学
肉毒杆菌毒素治疗美国$708 $626 $1,988 $1,827 
国际140 122 422 388 
总计$848 $748 $2,410 $2,215 
Vraylar美国$873 $750 $2,338 $1,967 
国际2 1 5 3 
总计$875 $751 $2,343 $1,970 
2024 Form 10-Q | abbvieimage2a21.gif
29

三个月结束了
九月三十日		九个月已经结束
九月三十日
（单位：百万）2024202320242023
duodopa美国$24 $25 $72 $74 
国际87 93 267 279 
总计$111 $118 $339 $353 
Ubrelvy美国$261 $230 $685 $574 
国际8 3 18 7 
总计$269 $233 $703 $581 
Qulipta美国$168 $131 $442 $292 
国际8 1 15 2 
总计$176 $132 $457 $294 
其他神经科学美国$54 $55 $172 $195 
国际30 6 66 15 
总计$84 $61 $238 $210 
眼部护理
Ozurdex美国$33 $34 $102 $107 
国际86 86 272 247 
总计$119 $120 $374 $354 
Lumigan/Ganfort美国$58 $28 $129 $142 
国际58 63 181 198 
总计$116 $91 $310 $340 
Alphagan/Combigan美国$26 $30 $54 $90 
国际36 40 116 116 
总计$62 $70 $170 $206 
静止状态美国$8 $104 $70 $265 
国际13 13 40 43 
总计$21 $117 $110 $308 
其他眼部护理美国$115 $114 $351 $334 
国际92 93 281 288 
总计$207 $207 $632 $622 
其他关键产品
Mavyret美国$147 $167 $458 $531 
国际155 203 562 590 
总计$302 $370 $1,020 $1,121 
Creon美国$338 $305 $995 $892 
Linzess/Constella美国$225 $279 $693 $799 
国际9 9 28 26 
总计$234 $288 $721 $825 
所有其他$726 $782 $2,280 $2,214 
净收入总额$14,460 $13,927 $41,232 $40,017 
(a)Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024.
2024 Form 10-Q | abbvieimage2a21.gif
30

项目2. 管理讨论与分析财务状况和业绩
以下是截至2024年9月30日和2023年12月31日艾伯维公司（AbbVie或公司）的财务状况及截至2024年9月30日和2023年的三个月和九个月业绩分析。本评论应与控件中出现的简明综合财务报表和附注一起阅读，“财务报表和附加资料”一节。
执行概述
公司概括
艾伯维公司是一家全球多元化的研究型生物制药公司，凭借免疫学、肿瘤学、美容、神经科学和眼科等领域的领先产品组合处于成功地位。艾伯维公司利用其专业知识、敬业人员和独特的创新方法来开发和推广解决世界上一些最复杂和严重疾病的先进治疗方案。
艾伯维公司于2024年8月1日完成了对cerevel therapeutics holdings inc.（Cerevel Therapeutics）的收购。 这一收购完善了艾伯维公司的神经科学投资组合，增添了一系列潜在一流资产，可能会改变精神病学和神经疾病治疗标准，在这些领域，患者仍然存在重大未满足的需求。 请参阅基本财务报表注释4，了解有关此收购的更多信息。 在收购日期之后，艾伯维公司的合并财务报表包括cerevel therapeutics的资产、负债、经营结果和现金流量。
2024年7月1日，艾伯维公司宣布前总裁兼首席运营官罗伯特 A. 迈克尔接替理查德 A. 冈萨雷斯成为公司的首席执行官（CEO）。自公司于2013年成立以来一直担任CEO的冈萨雷斯先生于2024年7月1日退任CEO一职，成为董事会执行主席。此外，董事会于2024年7月1日任命迈克尔先生为董事会成员。
2024年2月12日，艾伯维公司完成了对Immunogen, Inc.（Immunogen）的收购。该收购进一步完善了艾伯维公司现有的新型靶向疗法和下一代免疫-oncology资产的实体瘤流水线，这些资产有可能在多个实体瘤和血液恶性肿瘤领域开发出新的治疗可能性。艾伯维公司和Immunogen公司的共同能力代表了向患者提供可能具有重大转化意义的抗体-药物联合治疗（ADC）therapy的机会。请参阅基本报表附注4以获取有关收购的详细信息。自收购日期以后，艾伯维公司的合并财务报表包括Immunogen的资产、负债、经营业绩和现金流量。
艾伯维公司的产品通常直接销售给批发商、经销商、政府机构、医疗保健机构、专业药店和独立零售商等，从艾伯维公司的分销中心和公共仓库发货。某些产品（包括美容产品和设备）也直接销售给医生和其他持证医疗保健者。在美国，艾伯维主要通过独立批发商分销药品，有些销售成直销给零售商、药店、患者或其他客户。在美国以外，艾伯维主要向批发商销售产品或通过分销商销售，并根据市场情况通过大部分为中心化的国家支付机构协商制定适当的报销条款。某些产品是与其他公司共同营销或推广的。艾伯维公司作为一个单一的全球业务部门运营，拥有约50,000名员工。
2024年的战略目标
艾伯维公司的使命是发现和开发创新药物和产品，解决当今的严重健康问题以及解决未来的医疗挑战，同时通过卓越的执行实现顶级财务表现。艾伯维打算通过多种方式来执行其策略并推进其使命，包括：(i) 最大化拥有多个长期增长驱动器的多元化营业收入的利益;(ii) 利用艾伯维商业实力和国际制造行业在治疗领域的优势，确保新产品推出的强有力的商业执行力;(iii) 继续在免疫学、肿瘤学、美容学、神经科学和眼科等领域的机会支持其管道的投资和扩展，以及在关键市场产品的不断投资;(iv) 通过生成大量的经营性现金流来支持创新研发的投资，并通过强大而增长的股息向股东返还现金，同时继续偿还债务。此外，艾伯维预计在未来12个月内有几项重要的临床试验的监管提交和数据发布。
2024年第三季度报表 | abbvieimage2a21.gif
31

财务结果
截至2024年9月30日的九个月，公司的财务表现包括全球净收入达412亿美元，运营收益达106亿美元，稀释每股收益达2.41美元，经营活动现金流为118亿美元。全球净收入报告基础增长3%，常态货币基础增长4%。
截至2024年9月30日，稀释每股收益为2.41美元，包括以下税后成本： (i) 49亿美元，用于无形资产摊销； (ii) 34亿美元，用于按公允价值计量的未决条件负债变动； (iii) 8.94亿美元，用于收购和整合费用，以及 (iv) 5.85亿美元，用于诉讼事项相关费用。此外，财务结果反映了继续资助艾伯维公司管道资产各阶段的支持和继续投资于艾伯维公司在市场上的品牌。
迄今为止，我们的研究和开发费用与AV-101的开发有关。研究和开发费用按照发生的原则确认，并将在收到将用于研究和开发的货物或服务之前支付的款项资本化，直至收到这些货物或服务。
研究和创新是艾伯维公司作为全球生物制药公司业务的基石。艾伯维公司长期的成功在很大程度上取决于其发现和开发创新产品、收购或与其他生物技术或药品公司合作开发的化合物的能力。
艾伯维公司目前的项目涵盖了约90种独立或联合研发、许可协议研发的化合物、装置或适应症，重点关注免疫学、肿瘤学、美容、神经科学和眼部护理等重要领域。其中约50个项目处于中晚期研发阶段。
以下部分总结了重要项目从中期开发阶段转换为晚期开发阶段以及重要晚期和注册项目的发展。艾伯维公司预计多个中期项目将在未来12个月内转入晚期项目阶段。
重要的计划和发展
免疫学
Rinvoq
•2024年1月，艾伯维公司启动了第3期临床试验，评估Rinvoq在符合全身治疗条件的成年人和青少年非分段性白癜风患者中的应用。
•2024年4月，艾伯维公司宣布，Rinvoq与26周类固醇逐渐减量疗程联合治疗对于巨细胞动脉炎（GCA）患者达到了主要终点的3期SELECt-GCA试验获得了积极的上市结果。
•2024年4月，艾伯维公司宣布了在青少年和成人中度至重度特应性皮炎患者身上评估Rinvoq与dupilumab进行头对头第3b/4级别升试验的阳性一线结果。在这项研究中，Rinvoq在主要终点和所有评定的次要终点上均显示出优越性。
•2024年6月，艾伯维公司宣布美国食品和药物管理局（FDA）已经批准了Rinvoq用于治疗两岁及以上患有活跃性多关节类风湿性关节炎（pJIA）和银屑病性关节炎（PsA）的小儿患者，前提是他们对一种或多种肿瘤坏死因子（TNF）抑制剂反应不佳或无法耐受。
•2024年7月，艾伯维公司宣布已向美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）提交了一项新适应症的申请，用于治疗成人巨细胞动脉炎患者。
Skyrizi
•2024年6月，艾伯维公司宣布，FDA已批准Skyrizi用于中度至严重活动性溃疡性结肠炎（UC）的成人。
•2024年7月，艾伯维公司宣布欧洲委员会(EC)已批准Skyrizi用于治疗在常规治疗或生物制剂治疗方面反应不佳、失去疗效或对其不耐的中度至重度活动性UC成人患者。
Lutikizumab
•2024年1月，艾伯维公司宣布了2期结果，结果显示中重度大汗性膿瘡（HS）成人，之前曾失败于抗TNF治疗的患者，在接受lutikizumab后，在第16周实现了更高的临床反应率，达到HS临床反应的主要终点。
2024年第三季度报表 | abbvieimage2a21.gif
32

•2024年7月，艾伯维公司启动了第三阶段临床试验，评估lutikizumab在中重度HS成年和青少年患者中的疗效。
肿瘤学
Epkinly
•2024年3月，艾伯维公司启动了一项第3期临床试验，评估Epkinly与利妥昔单抗和来那度胺联合治疗未经治疗的激素瘤患者（FL）。
•2024年6月，艾伯维公司宣布，FDA已批准Epkinly用于治疗成人在经历两种或两种以上之前治疗方案后出现复发或难治性（R/R）的FL。该适应症是基于整体反应率（ORR）和反应持久性获得FDA加速批准计划的批准。该适应症的继续批准可能取决于在确认性试验中验证和描述临床益处。
•2024年6月，艾伯维公司宣布，欧洲药品管理局人用药品委员会已通过了一个积极意见，推荐将Tepkinly作为一种单药疗法，用于治疗经历两种或两种以上前期治疗后晚期复发的成年患者。
•2024年8月，艾伯维公司宣布欧盟委员会已经授予Tepkinly作为单药治疗成人反复发作FL患者的条件性上市授权，该患者在之前接受两种或更多种治疗方案后。
Elahere
•2024年3月，艾伯维公司宣布，美国食品和药物管理局已针对接受最多3种既往治疗的叶酸受体α（FRα）阳性、铂金耐药性的子宫内膜癌、输卵管癌或原发性腹膜癌患者，为Elahere药物批准了全面的治疗许可。
•2024年6月，艾伯维公司宣布了来自PICCOLO试验的一期研究Topline结果，评估在对FRα阳性、对铂金敏感的卵巢癌患者中进行了单药治疗的Elahere。该研究达到了其主要终点，并且没有发现新的安全问题。
•2024年9月，艾伯维公司宣布欧洲药品管理局人用药品委员会已通过了一项积极意见，推荐批准Elahere用于治疗已接受一至三个先前治疗方案的FRα阳性、铂金耐药性和高级别浆液性卵巢、输卵管或原发性腹膜癌的成年患者。
Navitoclax
•2024年4月，艾伯维公司宣布决定终止第3期TRANSFORm-2研究，评估navitoclax联合ruxolitinib治疗R/R骨髓纤维化患者，在评估第3期TRANSFORm-1试验数据总体情况和监管机构反馈后。
ABBV-383
•2024年6月，艾伯维公司启动了CERVINO第3期临床试验，以评估ABBV-383单药疗法与成人R/R多发性骨髓瘤患者先前接受过至少两条治疗线的标准可用治疗的比较。

Teliso-V

•2024年9月，艾伯维公司宣布向FDA提交生物制品许可申请，用于加速批准Teliso-V治疗已接受治疗的成年患者，局部晚期或转移性表皮生长因子受体（EGFR）野生型，非鳞状非小细胞肺癌（NSCLC），并且具有c-Met蛋白过表达。

美容领域

Juvederm系列

•2024年3月，艾伯维公司宣布FDA批准Juvederm Voluma XC用于在太阳穴地域板块注射，以改善21岁以上成年人中严重或中度太阳穴凹陷。
2024年第三季度报表 | abbvieimage2a21.gif
33

Botox化妆品
•2024年9月， 艾伯维公司宣布肉毒杆菌化妆品现在可以用于治疗中国的咬肌肌肉突出（MMP）问题。
•2024年10月，艾伯维公司宣布，美国食品药品监督管理局已批准Botox化妆品，用于暂时改善成年人下颌和颈部之间连接的中等至重度垂直条纹（颈部皱部）的外观。.
神经科学
维亚列夫
•2024年1月，艾伯维公司宣布在欧盟推出Produodopa（ABBV-951），用于治疗爱文思控股运动波动和高动力（过度运动）或运动障碍（非自愿运动）较为严重的帕金森病患者，以及当帕金森药物联合应用未取得满意效果时。
•2024年6月，艾伯维公司宣布其在新药申请(NDA)中针对ABBV-951治疗晚期帕金森病成人患者的运动波动收到了FDA的完整回复函(CRL)。FDA在回复函中提到了在对NDA中列出的第三方制造商进行检查时发现的一些观察结果。回复函并未发现与ABBV-951的安全性、有效性或标签相关的任何问题，包括设备，并且并未要求艾伯维公司进行与药物或设备相关的额外有效性或安全性试验。
•2024年10月，艾伯维公司宣布美国食品药品监督管理局已批准Vyalev（ABBV-951）作为首个也是唯一一个皮下24小时泵注射的左多巴疗法，用于治疗爱文思控股公司成人晚期帕金森病的运动波动。
Tavapadon
•2024年9月，艾伯维公司宣布了Tavapadon作为早期帕金森病单药治疗的III期TEMPO-1试验的积极上线结果。
了解更多关于艾伯维公司产品和开发管线的综合信息，请参阅该公司于2023年12月31日结束的年度报告在10-K表格中。
2024年第三季度报表 | abbvieimage2a21.gif
34

经常亏损。我们的财务报表已经假定我们将继续作为一个持续经营的实体，并相应地不包括有关资产清收和实现以及负债分类的调整，如果我们无法继续经营，则可能需要这些调整。
Net Revenues
以恒定的货币汇率计算的比较反映了去年外汇汇率下的比较本地货币净收入。该指标提供了在假设外汇汇率在前后期间未发生变化的情况下，净收入的变化情况。艾伯维公司认为，在实际货币汇率的GAAP利润变化指标和恒定货币汇率下的非GAAP利润变化指标同时使用时，可以更全面地理解公司的运营情况，并有助于分析公司的业绩表现，特别是在评估一个时期与另一个时期的表现时。
截至三个月结束
September 30,		百分比变化九个月结束
September 30,		百分比变化
根据实际汇率
货币汇率		以不变汇率计算
货币汇率不变		根据实际货币汇率
货币汇率		根据恒定货币汇率
恒定货币汇率
(单位：百万美元)
2024202320242023
美国
$11,148 $10,852 2.7 %2.7 %$31,295 $30,773 1.7 %1.7 %
国际
3,312 3,075 7.7 %12.4 %9,937 9,244 7.5 %12.2 %
净利润
$14,460 $13,927 3.8 %4.9 %$41,232 $40,017 3.0 %4.1 %
2024年第三季度报表 | abbvieimage2a21.gif
35

以下表格详细列出了艾伯维公司全球净收入：
截至三个月结束
September 30,		百分比变化九个月结束
September 30,		百分比变化
根据实际汇率
货币汇率不变		以不变汇率计算
货币汇率		在实际
货币汇率		在恒定
货币汇率
(单位：百万美元)
2024202320242023
免疫学
Humira美国$1,765 $3,020 (41.6)%(41.6)%$5,896 $9,420 (37.4)%(37.4)%
国际462 527 (12.4)%(7.8)%1,415 1,680 (15.8)%(10.8)%
总计$2,227 $3,547 (37.2)%(36.5)%$7,311 $11,100 (34.1)%(33.3)%
Skyrizi美国$2,778 $1,875 48.3 %48.3 %$6,774 $4,648 45.8 %45.8 %
国际427 251 70.0 %75.7 %1,166 721 61.8 %66.6 %
总计$3,205 $2,126 50.8 %51.5 %$7,940 $5,369 47.9 %48.5 %
Rinvoq美国$1,170 $801 45.9 %45.9 %$2,912 $1,895 53.6 %53.6 %
国际444 309 44.0 %51.6 %1,225 819 49.6 %58.5 %
总计$1,614 $1,110 45.3 %47.4 %$4,137 $2,714 52.4 %55.1 %
肿瘤学
Imbruvica美国$618 $678 (8.9)%(8.9)%$1,823 $1,982 (8.0)%(8.0)%
合作收入210 230 (8.4)%(8.4)%676 711 (4.9)%(4.9)%
总计$828 $908 (8.8)%(8.8)%$2,499 $2,693 (7.2)%(7.2)%
Venclexta美国$340 $281 21.5 %21.5 %$921 $811 13.6 %13.6 %
国际337 309 8.9 %15.4 %1,007 888 13.4 %19.7 %
总计$677 $590 14.8 %18.2 %$1,928 $1,699 13.5 %16.8 %
Elahere(a)
美国
$139 $— n/mn/m$331 $— n/mn/m
Epkinly
合作收入
$31 $14 >100.0 %>100.0 %$82 $14 >100.0 %>100.0 %
国际12 — >100.0 %>100.0 %24 — >100.0 %>100.0 %
总计$43 $14 >100.0 %>100.0 %$106 $14 >100.0 %>100.0 %
美容领域
Botox化妆品美国$414 $388 6.5 %6.5 %$1,253 $1,217 2.9 %2.9 %
国际257 232 10.9 %15.5 %780 747 4.5 %9.1 %
总计$671 $620 8.2 %9.9 %$2,033 $1,964 3.5 %5.3 %
Juvederm系列美国$105 $116 (10.2)%(10.2)%$349 $363 (4.1)%(4.1)%
国际153 205 (25.1)%(20.8)%549 681 (19.3)%(14.6)%
总计$258 $321 (19.7)%(16.9)%$898 $1,044 (14.0)%(10.9)%
其他美容产品美国$272 $255 6.4 %6.4 %$828 $785 5.6 %5.6 %
国际38 43 (10.0)%(2.0)%119 130 (8.7)%(1.8)%
总计$310 $298 4.0 %5.1 %$947 $915 3.5 %4.5 %
神经科学
Botox治疗产品美国$708 $626 13.1 %13.1 %$1,988 $1,827 8.8 %8.8 %
国际140 122 14.6 %20.7 %422 388 8.6 %13.1 %
总计$848 $748 13.4 %14.4 %$2,410 $2,215 8.8 %9.6 %
Vraylar美国$873 $750 16.5 %16.5 %$2,338 $1,967 18.9 %18.9 %
国际2 1 49.3 %51.9 %5 3 76.0 %76.9 %
总计$875 $751 16.6 %16.6 %$2,343 $1,970 18.9 %18.9 %
Duodopa美国$24 $25 (4.7)%(4.7)%$72 $74 (3.3)%(3.3)%
国际87 93 (7.1)%(6.4)%267 279 (4.4)%(4.0)%
总计$111 $118 (6.6)%(6.0)%$339 $353 (4.1)%(3.8)%
Ubrelvy美国$261 $230 13.6 %13.6 %$685 $574 19.3 %19.3 %
国际8 3 >100.0 %>100.0 %18 7 >100.0 %>100.0 %
总计$269 $233 15.3 %15.3 %$703 $581 20.9 %20.9 %
Qulipta美国$168 $131 28.3 %28.3 %$442 $292 51.3 %51.3 %
国际8 1 >100.0 %>100.0 %15 2 >100.0 %>100.0 %
总计$176 $132 33.6 %33.6 %$457 $294 55.5 %55.5 %
2024 Form 10-Q | abbvieimage2a21.gif
36

Three months ended
September 30,		Percent changeNine months ended
September 30,		Percent change
At actual
currency rates		At constant
currency rates		At actual
currency rates		At constant
currency rates
(dollars in millions)
2024202320242023
Other NeuroscienceUnited States$54 $55 (4.1)%(4.1)%$172 $195 (11.6)%(11.6)%
International30 6 >100.0 %>100.0 %66 15 >100.0 %>100.0 %
Total$84 $61 36.4 %37.1 %$238 $210 13.5 %14.1 %
Eye Care
OzurdexUnited States$33 $34 (2.3)%(2.3)%$102 $107 (4.4)%(4.4)%
International86 86 (0.3)%2.5 %272 247 10.0 %13.1 %
Total$119 $120 (0.9)%1.1 %$374 $354 5.7 %7.8 %
Lumigan/GanfortUnited States$58 $28 >100.0 %>100.0 %$129 $142 (9.5)%(9.5)%
International58 63 (7.0)%(2.7)%181 198 (8.7)%(5.9)%
Total$116 $91 27.2 %30.2 %$310 $340 (9.0)%(7.4)%
Alphagan/CombiganUnited States$26 $30 (15.3)%(15.3)%$54 $90 (40.3)%(40.3)%
International36 40 (10.0)%(4.5)%116 116 (0.1)%6.9 %
Total$62 $70 (12.3)%(9.2)%$170 $206 (17.7)%(13.8)%
RestasisUnited States$8 $104 (92.5)%(92.5)%$70 $265 (73.4)%(73.4)%
International13 13 2.1 %8.1 %40 43 (7.4)%(2.2)%
Total$21 $117 (82.2)%(81.5)%$110 $308 (64.2)%(63.5)%
Other Eye CareUnited States$115 $114 1.7 %1.7 %$351 $334 5.3 %5.3 %
International92 93 (2.0)%4.2 %281 288 (2.4)%2.1 %
Total$207 $207 — %2.8 %$632 $622 1.7 %3.8 %
Other Key Products
MavyretUnited States$147 $167 (12.7)%(12.7)%$458 $531 (13.9)%(13.9)%
International155 203 (23.1)%(20.5)%562 590 (4.6)%(1.2)%
Total$302 $370 (18.4)%(17.0)%$1,020 $1,121 (9.0)%(7.2)%
CreonUnited States$338 $305 10.6 %10.6 %$995 $892 11.5 %11.5 %
Linzess/ConstellaUnited States$225 $279 (19.2)%(19.2)%$693 $799 (13.2)%(13.2)%
International9 9 0.4 %2.0 %28 26 6.2 %6.0 %
Total$234 $288 (18.6)%(18.6)%$721 $825 (12.6)%(12.6)%
All other$726 $782 (6.8)%(5.5)%$2,280 $2,214 3.0 %4.6 %
Total net revenues$14,460 $13,927 3.8 %4.9 %$41,232 $40,017 3.0 %4.1 %
n/m – Not meaningful
(a)Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024.
The following discussion and analysis of AbbVie’s net revenues by product is presented on a constant currency basis.
Global Humira sales decreased 37% for the three months and 33% for the nine months ended September 30, 2024. In the United States, Humira sales decreased by 42% for the three months and 37% for the nine months ended September 30, 2024 primarily driven by direct biosimilar competition following the loss of exclusivity on January 31, 2023. Internationally, Humira revenues decreased 8% for the three months and 11% for the nine months ended September 30, 2024 primarily driven by the continued impact of direct biosimilar competition. AbbVie continues to pursue strategies to maintain broad formulary access of Humira and manage the impact of biosimilar erosion.
Net revenues for Skyrizi increased 51% for the three months and 49% for the nine months ended September 30, 2024 primarily driven by continued strong market share uptake as well as market growth across all indications.
Net revenues for Rinvoq increased 47% for the three months and 55% for the nine months ended September 30, 2024 primarily driven by continued strong market share uptake as well as market growth across all indications.
Net revenues for Imbruvica represent product revenues in the United States and collaboration revenues outside of the United States related to AbbVie’s 50% share of Imbruvica profit. AbbVie's global Imbruvica revenues decreased 9% for the three months and 7% for the nine months ended September 30, 2024 primarily driven by decreased demand and lower market share in the United States as well as decreased collaboration revenues.
Net revenues for Venclexta increased 18% for the three months and 17% for the nine months ended September 30, 2024 primarily driven by continued market share uptake and market growth across all indications.
2024 Form 10-Q | abbvieimage2a21.gif
37

Net revenues for Elahere were $139 million for the three months and $331 million for the nine months ended September 30, 2024 for the period subsequent to the completion of the ImmunoGen acquisition.
Net revenues for Botox Cosmetic increased 10% for the three months and 5% for the nine months ended September 30, 2024 primarily driven by favorable pricing. Net revenues for the nine months ended September 30, 2024 were also partially offset by the unfavorable impact of customer inventory destocking in the United States.
Net revenues for Juvederm Collection decreased 17% for the three months and 11% for the nine months ended September 30, 2024 primarily driven by decreased consumer demand across international markets. Net revenues for the nine months ended September 30, 2024 were also unfavorably impacted by customer inventory destocking in the United States.
Net revenues for Botox Therapeutic increased 14% for the three months and 10% for the nine months ended September 30, 2024 primarily driven by continued market share uptake as well as market growth.
Net revenues for Vraylar increased 17% for the three months and 19% for the nine months ended September 30, 2024 primarily driven by continued market share uptake as well as market growth.
Net revenues for Ubrelvy increased 15% for the three months and 21% for the nine months ended September 30, 2024 primarily driven by continued market share uptake as well as market growth.
Net revenues for Qulipta increased 34% for the three months and 56% for the nine months ended September 30, 2024 primarily driven by continued strong market share uptake as well as market growth.
Gross Margin
Three months ended
September 30,		Nine months ended
September 30,
(dollars in millions)20242023% change20242023% change
Gross margin$10,248$7,44238 %$28,724$25,30614 %
as a % of net revenues71 %53 %70 %63 %
Gross margin as a percentage of net revenues increased for the three and nine months ended September 30, 2024 compared to the prior year. Gross margin percentage for the three and nine months ended September 30, 2024 was favorably impacted by lower amortization of intangibles and lower intangible asset impairment charges. The three months ended September 30, 2023 included intangible asset impairment charges of $2.1 billion.
Selling, General and Administrative
Three months ended
September 30,		Nine months ended
September 30,
(dollars in millions)20242023% change20242023% change
Selling, general and administrative $4,205$3,37225 %$10,897$9,67913 %
as a % of net revenues29 %24 %26 %24 %
Selling, general and administrative (SG&A) expenses as a percentage of net revenues increased for the three and nine months ended September 30, 2024 compared to the prior year. SG&A expense was unfavorably impacted by higher litigation reserve charges and acquisition and integration costs incurred in connection with the ImmunoGen and Cerevel Therapeutics acquisitions including cash-settled, post-closing expense for both ImmunoGen and Cerevel Therapeutics employee incentive awards, partially offset by the favorable impact of leverage from revenue growth. See Note 4 to the Condensed Consolidated Financial Statements for additional information.
2024 Form 10-Q | abbvieimage2a21.gif
38

Research and Development
Three months ended
September 30,		Nine months ended
September 30,
(dollars in millions)20242023% change20242023% change
Research and development$2,130 $1,723 24 %$6,017$5,7485 %
as a % of net revenues15 %12 %15 %14 %
Research and development (R&D) expenses as a percentage of net revenues increased for the three and nine months ended September 30, 2024 compared to the prior year. R&D expense percentage for the three and nine months ended September 30, 2024 was unfavorably impacted by increased funding to support all stages of the company’s pipeline assets as well as acquisition and integration costs incurred in connection with the ImmunoGen and Cerevel Therapeutics acquisitions including cash-settled, post-closing expense for employee incentive awards. See Note 4 to the Condensed Consolidated Financial Statements for additional information. R&D expense percentage increase for the nine months ended September 30, 2024 was partially offset by lower intangible asset impairment charges. The nine months ended September 30, 2023 included an intangible asset impairment charge of $630 million.
Acquired IPR&D and Milestones
Three months ended
September 30,		Nine months ended
September 30,
(dollars in millions)2024202320242023
Upfront charges$82 $44 $1,088 $396 
Development milestones— 22 95 100 
Acquired IPR&D and milestones$82 $66 $1,183 $496 
Acquired IPR&D and milestones expense for the nine months ended September 30, 2024 included a charge related to the upfront payment of $250 million to acquire Celsius Therapeutics. See Note 4 to the Condensed Consolidated Financial Statements for additional information.
Other Non-Operating Expenses (Income)
Three months ended
September 30,		Nine months ended
September 30,
(in millions)2024202320242023
Interest expense$720 $555 $2,106 $1,660 
Interest income(129)(157)(556)(354)
Interest expense, net$591 $398 $1,550 $1,306 
Net foreign exchange loss (gain)$(3)$25 $2 $97 
Other expense (income), net1,159 (95)3,090 3,121 
Interest expense increased for the three and nine months ended September 30, 2024 compared to the prior year primarily due to the incremental interest associated with financing the ImmunoGen and Cerevel Therapeutics acquisitions. See Note 8 to the Condensed Consolidated Financial Statements for additional information related to debt issued to finance the ImmunoGen and Cerevel Therapeutics acquisitions.
Interest income decreased for the three months ended September 30, 2024 compared to the prior year primarily due to a lower average cash and cash equivalents balance. Interest income increased for the nine months ended September 30, 2024 compared to the prior year primarily due to a higher average cash and cash equivalents balance and the impact of higher interest rates.
Other expense (income), net included charges related to changes in fair value of contingent consideration liabilities of $1.4 billion for the three months and $3.5 billion for the nine months ended September 30, 2024 and $8 million for the three months and $3.4 billion for the nine months ended September 30, 2023. The fair value of contingent consideration liabilities is impacted by the passage of time and multiple other inputs, including the probability of success of achieving regulatory milestones, discount rates, the estimated amount of future sales of the acquired products and other market-based factors. For the three and nine months ended September 30, 2024, the change in fair value reflected higher estimated Skyrizi sales and the passage of time. For the three months ended September 30, 2024, the change in fair value also reflected the impact of lower discount rates. For the three months ended September 30, 2023, the change in fair value reflected the passage of time offset by higher discount rates. For the nine months
2024 Form 10-Q | abbvieimage2a21.gif
39

ended September 30, 2023, the change in fair value reflected higher Skyrizi sales driven by stronger market share uptake and the passage of time, partially offset by higher discount rates.
Income Tax Expense
The effective tax rate was 25% for the three months and 28% for the nine months ended September 30, 2024 compared to 9% for the three months and 20% for the nine months ended September 30, 2023. The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, changes in fair value of contingent consideration and business development activities, including ImmunoGen and Cerevel Therapeutics acquisition-related costs. The increase in the effective tax rate for the three months ended September 30, 2024 over the prior year was primarily due to changes in fair value of contingent consideration, impact of foreign operations and business development activities. The increase in the effective tax rate for the nine months ended September 30, 2024 over the prior year was primarily due to the impact of foreign operations and business development activities.
Subsequent to September 30, 2024, the company was notified that the administrative proceeding related to its U.S. federal income tax examination for certain tax years was substantially completed. Final resolution of examination of such years may occur in the fourth quarter of 2024. The company anticipates that final resolution will result in a decrease in the gross amount of unrecognized tax benefits on the condensed consolidated balance sheets and recognition of an income tax benefit in the condensed consolidated statement of earnings, which could be material. The Company does not anticipate that such resolution will have a significant impact on its cash flows.
FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES
Nine months ended
September 30,
(in millions)20242023
Cash flows provided by (used in):
Operating activities$11,758 $18,086 
Investing activities(18,946)(1,209)
Financing activities1,650 (12,773)
Operating cash flows for the nine months ended September 30, 2024 decreased compared to the prior year primarily due to the timing of working capital, higher contingent consideration payments classified as operating cash flows and decreased results from operations driven by ImmunoGen and Cerevel Therapeutics acquisition-related cash expenses.
Investing cash flows for the nine months ended September 30, 2024 included $18.5 billion cash consideration paid to acquire ImmunoGen and Cerevel Therapeutics offset by cash acquired of $952 million, net sales and maturities of investment securities of $470 million, payments made for other acquisitions and investments of $1.2 billion and capital expenditures of $683 million. Investing cash flows for the nine months ended September 30, 2023 included payments made for other acquisitions and investments of $670 million and capital expenditures of $572 million.
Financing cash flows for the nine months ended September 30, 2024 included the issuance of unsecured senior notes totaling $15.0 billion aggregate principal which were used to finance the acquisitions of ImmunoGen and Cerevel Therapeutics. Additionally, financing cash flows included the issuance and repayment of $5.0 billion under the term loan credit agreement and repayments of €1.5 billion aggregate principal amount of 1.38% senior euro notes, €700 million aggregate principal amount of 1.25% senior euro notes, $1.0 billion aggregate principal amount of 3.85% senior notes, $99 million of secured term notes assumed from ImmunoGen in conjunction with the acquisition and the settlement of $400 million aggregate amount of 2.5% convertible senior notes assumed from Cerevel Therapeutics. Financing cash flows for the nine months ended September 30, 2023 included repayments of $1.0 billion floating rate term loan, $1.0 billion aggregate principal amount of 2.85% senior notes and $350 million aggregate principal amount of the company’s 2.80% senior notes.
Subsequent to September 30, 2024, the company refinanced its $2.0 billion floating rate three-year term loan. As part of the refinancing, the company repaid the existing $2.0 billion term loan due May 2025 and borrowed $2.0 billion under a new term loan due April 2027.
Financing cash flows also included cash dividend payments of $8.3 billion for the nine months ended September 30, 2024 and $7.9 billion for the nine months ended September 30, 2023. The increase in cash dividend payments was primarily driven by the increase in the quarterly dividend rate.
2024 Form 10-Q | abbvieimage2a21.gif
40

On September 6, 2024, the company announced that its board of directors declared a quarterly cash dividend of $1.55 per share for stockholders of record at the close of business on October 15, 2024, payable on November 15, 2024. On October 30, 2024, the board of directors declared an increase in the company’s quarterly dividend from $1.55 per share to $1.64 per share beginning with the dividend payable on February 14, 2025 to stockholders of record as of January 15, 2025. This reflects an increase of approximately 5.8% over the previous quarterly rate. The timing, declaration, amount of and payment of any dividends by AbbVie in the future is within the discretion of its board of directors and will depend upon many factors, including AbbVie’s financial condition, earnings, capital requirements of its operating subsidiaries, covenants associated with certain of AbbVie’s debt service obligations, legal requirements, regulatory constraints, industry practice, ability to access capital markets and other factors deemed relevant by its board of directors.
The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. On February 16, 2023, AbbVie’s board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization. AbbVie repurchased 5 million shares for $959 million during the nine months ended September 30, 2024 and 10 million shares for $1.6 billion during the nine months ended September 30, 2023.
Financing cash flows also included contingent consideration payments of $735 million for the nine months ended September 30, 2023. There were no contingent consideration payments classified as financing cash flows for the nine months ended September 30, 2024.
During the nine months ended September 30, 2024, the company issued and redeemed $1.7 billion of commercial paper. There were no commercial paper borrowings outstanding as of September 30, 2024 and December 31, 2023. AbbVie may issue additional commercial paper or retire commercial paper to meet liquidity requirements as needed.
Credit Risk
AbbVie monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. AbbVie regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. AbbVie establishes an allowance for credit losses equal to the estimate of future losses over the contractual life of outstanding accounts receivable. AbbVie may also utilize factoring arrangements to mitigate credit risk, although the receivables included in such arrangements have historically not been a significant amount of total outstanding receivables.
Credit Facility, Access to Capital and Credit Ratings
Credit Facility
In December 2023, in connection with the acquisitions of ImmunoGen and Cerevel Therapeutics, AbbVie entered into a $9.0 billion 364-day bridge credit agreement and $5.0 billion 364-day term loan credit agreement. In February, 2024, AbbVie borrowed and repaid $5.0 billion under the term loan credit agreement. Subsequent to the $15.0 billion issuance of senior notes, AbbVie terminated both the bridge and term loan credit agreements in the first quarter of 2024.
In March 2023, AbbVie entered into an amended and restated five-year revolving credit facility. The amendment increased the unsecured revolving credit facility commitments from $4.0 billion to $5.0 billion and extended the maturity date of the facility from August 2023 to March 2028. This credit facility enables the company to borrow funds on an unsecured basis at variable interest rates and contains various covenants. At September 30, 2024, the company was in compliance with all covenants, and commitment fees under the credit facility were insignificant. No amounts were outstanding under the company's credit facility as of September 30, 2024 and December 31, 2023.
Access to Capital
The company intends to fund short-term and long-term financial obligations as they mature through cash on hand, future cash flows from operations or has the ability to issue additional debt. The company’s ability to generate cash flows from operations, issue debt or enter into financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for the company’s products or in the solvency of its customers or suppliers, deterioration in the company’s key financial ratios or credit ratings or other material unfavorable changes in business conditions. At the current time, the company believes it has sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support the company’s growth objectives.
2024 Form 10-Q | abbvieimage2a21.gif
41

Credit Ratings
In August 2024, Moody’s Investors Service (Moody’s) affirmed its A3 senior unsecured long-term rating. At the same time, Moody’s revised its outlook to positive from stable. There were no other changes in the company’s credit ratings during the nine months ended September 30, 2024. Unfavorable changes to the ratings may have an adverse impact on future financing arrangements; however, they would not affect the company’s ability to draw on its credit facility and would not result in an acceleration of scheduled maturities of any of the company’s outstanding debt.
CRITICAL ACCOUNTING POLICIES
A summary of the company’s significant accounting policies is included in Note 2, “Summary of Significant Accounting Policies” in AbbVie's Annual Report on Form 10-K for the year ended December 31, 2023. There have been no significant changes in the company’s application of its critical accounting policies during the nine months ended September 30, 2024.
FORWARD-LOOKING STATEMENTS
Some statements in this quarterly report on Form 10-Q are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project,” and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” in AbbVie’s Annual Report on Form 10-K for the year ended December 31, 2023, which has been filed with the Securities and Exchange Commission. AbbVie notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
For a discussion of the company's market risk, see Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" in AbbVie's Annual Report on Form 10-K for the year ended December 31, 2023.
ITEM 4. CONTROLS AND PROCEDURES
DISCLOSURE CONTROLS AND PROCEDURES
Evaluation of disclosure controls and procedures. The Chief Executive Officer, Robert A. Michael, and the Chief Financial Officer, Scott T. Reents, evaluated the effectiveness of AbbVie's disclosure controls and procedures as of the end of the period covered by this report, and concluded that AbbVie's disclosure controls and procedures were effective to ensure that information AbbVie is required to disclose in the reports that it files or submits with the Securities and Exchange Commission under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms, and to ensure that information required to be disclosed by AbbVie in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to AbbVie's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
INTERNAL CONTROL OVER FINANCIAL REPORTING
Changes in internal control over financial reporting. There were no changes in AbbVie's internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934) that have materially affected, or are reasonably likely to materially affect, AbbVie's internal control over financial reporting during the quarter ended September 30, 2024.
Inherent Limitations on Effectiveness of Controls. AbbVie’s management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie’s disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or
2024 Form 10-Q | abbvieimage2a21.gif
42

that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls.
The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.
2024 Form 10-Q | abbvieimage2a21.gif
43

PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Information pertaining to legal proceedings is provided in Note 12 to the Condensed Consolidated Financial Statements and is incorporated by reference herein.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(c) Issuer Purchases of Equity Securities

Period
(a) Total
Number of
Shares 
(or Units)
Purchased
(b) Average
Price Paid
per Share
(or Unit)		(c) Total Number
of Shares (or
Units) Purchased
as Part of Publicly
Announced Plans
or Programs

(d) Maximum
Number (or
Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs
July 1, 2024 - July 31, 2024974 
(1)
$166.09
(1)
— $3,849,610,303
August 1, 2024 - August 30, 2024856 
(1)
$186.04
(1)
— $3,849,610,303
September 1, 2024 - September 30, 2024902 
(1)
$193.39
(1)
— $3,849,610,303
Total2,732 
(1)
$181.36
(1)
— $3,849,610,303

1.In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 974 in July; 856 in August; and 902 in September.
These shares do not include the shares surrendered to AbbVie to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.
ITEM 5. OTHER ITEMS
(c) Director and Officer Trading Arrangements
During the three months ended September 30, 2024, no director or officer of the company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.


2024 Form 10-Q | abbvieimage2a21.gif
44

ITEM 6. EXHIBITS

Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.

Exhibit No.Exhibit Description
101
The following financial statements and notes from the AbbVie Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed on November 4, 2024, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Earnings; (ii) Condensed Consolidated Statements of Comprehensive Income; (iii) Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Equity; (v) Condensed Consolidated Statements of Cash Flows; and (vi) the Notes to Condensed Consolidated Financial Statements.
104Cover Page Interactive Data File (the cover page from the AbbVie Inc. Quarterly Report on Form 10-Q formatted as Inline XBRL and contained in Exhibit 101).

_______________________________________________________________________________



2024 Form 10-Q | abbvieimage2a21.gif
45

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


ABBVIE INC.
By:
/s/ Scott T. Reents
Scott T. Reents
Executive Vice President,
Chief Financial Officer (Principal Financial Officer)


Date: November 4, 2024


2024 Form 10-Q | abbvieimage2a21.gif
46